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ABSTRACT
The advancement in laparoscopic and robotic surgeries is calling for innovation in
wound closure methods where the classical mechanical ligatures are proving very
challenging due to reduction in surgical spaces, even for seasoned surgeons.1–3 Tissue
adhesives have been investigated as an alternative and/or adjuvant method to address
some of these unmet needs. Previously in our lab, Sanders and co-workers4 developed a
successful synthetic adhesive by modifying Tetronic 1107 to incorporate acrylate (ACR)
for chemical crosslinking and N-hydroxisuccinimide (NHS) to enhance tissue bonding,
improving the seminal work done by Cho et al.5 However, solutions of modified T1107
would undergo reverse thermal gelation below room temperature, imposing a usability
limitation since they could gel while being handled, and a functional limitation because if
the material gelled to fast it would not make a good contact with the microstructure of the
underlying tissues. Therefore, the main objective of this master’s thesis research is to
further improve the performance of these Tetronic-based adhesives by controlling the
gelation temperature of these polymeric systems. To control the gelation temperatures of
functionalized T1107 blends solutions, the acrylated version of a lower molecular
Tetronic, T304, was incorporated into these polymers blends. This strategy proved to be
effective to control de gelation temperature of the Tetronic-based adhesives, and also
extended their degradation times. However, increased amounts of T304-ACR were
correlated with lower adhesive strengths. With the right blend ratio, these three properties
can be balanced to yield a mechanically strong adhesive, with a useful degradation profile
and controlled gelation temperature.
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CHAPTER ONE
INTRODUCTION AND BACKGROUND

1.1 Introduction
Many surgical challenges are fueling the exploration of new wound closure
techniques. The goals of such endeavor include, but are not limited to, reducing the
surgical times and costs, reducing learning curves for surgical procedures, reducing
hospital-acquired infections, reducing invasiveness of procedures, minimizing scar tissue
formation, improving sealing around the closure line, decreasing bleeding, reducing
procedure related morbidity, diminishing hospital stay, etc. Currently, as it has been since
the time of the Egyptians,6 the wound closure method of reference is the use of sutures;
however, there are a list of undeniable downsides associated with them. Tissue adhesives
have been investigated as an alternative and/or adjuvant method to overcome some of
these unmet needs. The miniaturization of surgical spaces, specially with the spreading of
laparoscopic and robotic surgeries, are opening a great avenue for new wound closure
methods where the classical mechanical ligatures are proving very challenging to be
performed, even for seasoned surgeons.
The first use of adhesive materials in medicine could be tracked back as far as 4000
years ago and the first use of fibrin in the modern medicine was reported in 1909.7
Despite this long history of research and development, the perfect tissue adhesive has yet
to be created, bearing in mind that the “one-fits-all” approach is not applicable to
adhesives for medical use.8 Each medical application calls for specific requirements, and
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tailor-made adhesives with particular properties are necessary. For instance, sealants used
in corneal repair needs to offer a similar refractive index to that of the cornea itself,8 and
it should not be a material one would expect to exhibit enough mechanical resistance to
secure a muscle incision. Overall, no tissue adhesive has reached enough adhesive and
cohesive strength to replace sutures as a reliable primary wound closure method, and
other limitations have also been described related but not limited to toxicity, degradation,
usability, costs, and safety.9,10

1.2 The ideal tissue adhesive for internal use in soft tissues
Although surgeons have lately seen an increased variety of wound closure products
and devices in their surgical toolboxes, none of these can claim to address all design
features of the ideal wound closure method.11 The scope of the present study is restricted
to wound closure methods used in internal soft tissue repair, and focusing particularly in
tissue adhesives. Even within these boundaries, the ideal product has yet to be available
commercially.
To establish the characteristics of an ideal tissue adhesive, it is necessary to first
identify the specific clinical need and agree on a definition for tissue adhesives. From a
clinical perspective, an unmet need still exists for a safe and efficient method to be used
in an operating room, or equivalent clinical setting, to secure the integrity of the union of
soft tissues, without interfering with the structure and physiological function of these
tissues. The union of soft tissues includes the re-approximation of disrupted or injured
tissues, the joining or anastomoses of different tissues, and the coupling of native tissue
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with a foreign material. Although a few techniques for relatively simple wound closures
with acceptable outcomes are available, there is still a lot to improve in more challenging
closures.
The definition of tissue adhesives is not as straightforward as it seems. While the
words tissue adhesives and tissue sealants are frequently use as synonyms, they are
actually making reference to different types of products with specific intended uses.1
Tissue adhesives are tacky materials that are applied to bind tissues providing the
mechanical strength to hold them together while the natural healing process occurs and
the structural integrity is recovered.1,12 Tissue sealants are intended to close tissue
defects13 and restore or create a physical barrier to avoid fluid leakage.14 However, it
should be noted that fluid leakage is different than blood loss through open or injured
vessels. The ability of generating a blood clot to stop the bleeding15 is shown by
hemostatic agents, or simply hemostats, which is a third group of materials, different
from adhesives or sealants. The ideal wound closure method should show the
characteristics of these three groups; adhesiveness, sealant capabilities, and hemostatic
function.16
Current solutions for wound closure exhibit limitations that are fueling the interest of
many researchers in the field of tissue adhesives. The following is a summary list of the
most relevant motivations for conducting research in tissue adhesives to overcome these
limitations.
•

To make application techniques easier with shorter learning curves, especially
in robotic and laparoscopic procedures1–3,17–19
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•

To achieve better leak-proof closures17,20–23

•

To reduce invasiveness of procedures and the post-operative morbidity,3,24–26

•

To reduce traumas for the tissues to bind (sutures and staples creates a
significant trauma along the closure line),27–30

•

To improve hemostasis3,18,31–33

•

To allow for application under wet environments,34–37

•

To reduce rates of infections,16,33,38,39

•

To ensure that material is not toxic and does not elicit an immune
response,40,41

•

To prevent scar tissue formation.42–44

Based on the identified clinical need, the definitions of different materials and
functions, the main motivations to improve current solutions, and finally on Bhatia’s
work on adhesive biomaterials38 we have defined four main requirements that any tissue
adhesive should excel in to be considered a gold standard in this field. These four
requirements are: 1) excellent physical and mechanical properties, 2) full
biocompatibility, 3) allow normal wound healing, and 4) usability and marketability.
These categories are a way of restating Spotnitz11 general requirements for an ideal tissue
adhesive: safety, efficacy, usability, cost and approvability (e.g. by FDA or CE mark).

1.2.1 MECHANCIAL PROPERTIES
The essential requirements pertaining physicochemical and mechanical properties
includes the level of adhesiveness and of cohesive integrity. Adhesive strength is needed
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to create a strong bond between the adhesive material and the tissues to be glued, while
cohesive forces are the responsible for keeping the bulk resistance under external
mechanical loads.31,45–47 Soft tissue adhesive must also demonstrate mechanical
compatibility with the underlying tissues. This requirement is often referred as
mechanical compliance and is of a fundamental importance when the adhesive is used on
elastic organs, such as the urinary bladder, the lungs or blood vessels.20,46 These
expandable organs undergo high levels of elastic stretching during their normal
functioning, and any material attached to them should follow these elastic movements to
allow the organs their normal range of motion, without being detached or broken and
without creating stress concentration areas due to an excessive rigidity.48 If too brittle, the
material would limit the mobility of the organ in that area, thus preventing the normal
function. This could have a negative impact not only at the function level but also on the
healing process. Finally, the physicochemical characteristics of the materials should
allow for a simple and adequate curing method,14,30,49,50 if the material needs to undergo
such a process. Hence, the user should be a passive witness of the curing process, which
must be able to occur rapidly in wet environments, under physiological
conditions.29,33,35,37
Most of synthetic materials implanted in the body need to be degraded at some point
and allow for a harmless clearance. The timing for the degradation process to be
completed is also of paramount importance since the adhesive cannot afford loosing its
mechanical stability by degradation before the wound is fully healed and the tissue or
organ is operational.51,52
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1.2.2 BIOCOMPATIBILITY
Many materials have shown good adhesives capabilities, but failed when it comes to
prove biocompatibility. The example most often cited is cyanoacrylates for internal use.
These materials have shown high adhesive strengths for topical uses,53 but at the same
time they elicited unacceptable levels of inflammation, cytotoxicity and other adverse
events when used within the body.1,14 At least some of these events have been associated
with their degradation products.41 It is imperative to test the effects of both the original
materials and their degradation products. The ‘ISO 10993 – Biological evaluation of
medical devices’ standard specifies some methodological guidelines on how to perform
these tests. It has also been required that the degradation products must follow the normal
physiological process to be removed from the body, i.e. excreted through the kidneys to
avoid the potentially harmful accumulation of these byproducts.38 Table 1.1 below
includes the most notorious biocompatibility characteristics that an ideal adhesive must
address to claim minimum safety.
Another biocompatibility issue arises when the base material can carry a foreign
biological load. Biologically derived adhesives and sealants are potential viral
transmission vectors54 and can also provoke disproportionate immune reactions.55 Last,
but certainly not least, bacteria must find very difficult to populate the material used to
manufacture the adhesive, or the adhesive/tissue interface. Ideally the material would not
promote bacterial adhesion and proliferation. However, if the risk of such an event is
present, complementary anti-infective approaches must be taken to minimize this
threat.38,56
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Table 1.1 Checklist for an ideal tissue adhesive. Adapted from Sujata et al.38
Requirements
1. Physicochemical an mechanical properties
1.1 Sufficient adhesion to the target tissue/s
1.2 Sufficient cohesive strength
1.3 Mechanical compliance
1.4 Simple and adequate curing method
2. Biocompatibility specifications
2.1 Material and degradation products: noncytotoxic, nonhemolytic,
noninflammatory, noncarcinognic
2.2 Cause no irritation or sensitization
2.3 Not induce an excessive immune response
2.4 Not promote bacterial proliferation
2.5 Degradation products must be metabolized or excreted via kidneys or liver
3. Normal wound healing
3.1 Allow wound healing with minimal interference
3.2 Avoid fibrosis or material encapsulation
3.3 Material degradation happens after wound healing is completed
4. Usability-based design and marketability
4.1 Short learning curve (procedure)
4.2 Ready-to-use device
4.3 Minimize the need for external equipment
4.4 Adequate shelf stability
4.5 Preferably it should be stored and transported at room temperature
4.6 Production should be scalable to industrial level
4.7 Product must be sterilizable
4.8 Reasonable cost or cost/effectiveness
4.9 Approvability.

Checkboxes

1.2.3 WOUND HEALING
Every wound closure method has the ultimate goal of providing a support structure to
allow integrity of the wound until it is completely healed; thus, it must not interfere with
the normal healing process.38,57 Encapsulations or scar formation are commonly seen
when the materials elicit a large foreign body response. An encapsulation can jeopardize
the adhesive function and any other type of fibrous tissue formation may negatively
influence the normal function of organs and tissues by limiting motion and elasticity,
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creating stress concentrations areas, restricting permeability and electrical conductibility,
just to mention a few consequences.58

1.2.4 USABILITY AND MARKETEABILITY
Any tissue adhesive aspiring to become the next gold standard, needs to become an
available product, meeting also usability, marketing and manufacturing requirements.
First of all, the final device must be an easy to use product, requiring from users the
regular skillset found in young surgeons. In order to accomplish this requirement, the
product should be associated with a very short learning curve. Excellent medical
solutions that need a complex surgical technique to be used correctly tend to show poor
performances in the hands of inexperienced surgeons. Furthermore, the costs derived
from medical training are a major factor in the cost structures of medical device
companies. The more complex the surgical technique more money will have to be
invested in medical training, and very likely, the device will be significantly more
expensive.
In addition to a short learning curve, the medical device should be ready to use and
add no cumbersome, time consuming steps.3,11 Reducing the intervention of the surgeon
or his collaborators in the operative room decreases both costs and the chance of userrelated errors dramatically. A counter example of this concept is represented by the
photocrosslinkable adhesives that need to be exposed to a light source to be cured, adding
a further step after the adhesive is applied, and adding external equipment to achieve the
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wound closure. Many authors are asking for eliminating the need of external equipment
to simplify procedures, reduce costs and extend the range of intended uses.24,38,59
From the industrial perspective there are four main requirements; scalability, shelf
stability, storage and transportation at room temperature, and sterility.16,38 The adhesive
manufacturing must be scalable to industrial levels, basically meaning that the raw
materials must be readily available and that the production in large quantities is feasible.
For instance, proteins found in mussels seem to be responsible for the ability of these
molluscs to stick to virtually any type of surface. However, the extraction of these
proteins from the mussels to make adhesives proved to be uneconomical for an industrial
level.8 This is the reason why synthetic alternatives to emulate these proteins activity are
now under investigation, in an attempt to produce similar results with available or labmade compounds.60
The price and/or the cost-benefit ratio associated with a new product are sometimes
underestimated. Unless the new product introduces a ground breaking feature for which
the customer would be willing to pay a premium, or has a competitive price, its market
penetration could be hindered by economical issues regardless its clinical performance.61
An initial market evaluation could evidence the economical feasibility or unfeasibility of
such a product. A factor that can have a huge impact on the product retail price is FDAapproval, or by other similar regulatory agencies in other parts of the world. Considering
the time, costs and resources that a FDA-approval process requires, it is mandatory to
address this issue from the early developmental stages. If impractical from the time or
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cost standpoints, another technical approach should be contemplated. Regulatory
approvability is undoubtedly a requirement at the top of the list.

1.3 Current and prospective wound closure methods
Despite the continuous launches of new wound closure products, sutures remain the
gold standard method.62 However, the use of complementary adhesives, sealants and
hemostats with sutures let us see that there is a need for a performance improvement in a
good number of applications. The clinical interest to find the device that can replace or
supplement sutures is still intact.16 The currently available wound closure products can
be grouped in four categories: mechanical fasteners, biologically derived tissue
adhesives, synthetic tissue adhesives, and other approaches. Some of the materials
presented in this section have not been used for internal applications yet, but could be
investigated for such use in the future or at least act as an inspiration for other new
products.

1.3.1 MECHANICAL FASTENERS
Sutures are defined as strands of material used to ligate or to approximate tissue
together,63 and are probably one of the first wound closures methods ever used. Sutures
are manufacture from a broad spectrum of materials that can be categorized in biologic or
synthetic and in absorbable or non- absorbable. The absorbable sutures can disappear
from the site of application in between 7 and 120 days. It is worth noting that a suture
usually loses its tensile strength way before its complete degradation. More recent
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advances in suture materials technology have brought antibiotic coated products and
knotless devices.64
The reason why sutures are the gold standard for almost every wound closure
technique relies on the fact that there is no other device that can compete with them in
terms of tensile strength, effectiveness in tissue approximation and low dehiscence rates.
However, a recent meta-analysis involving comparisons between tissue adhesives and
sutures concluded that sutures are significant better in minimizing dehiscence, although
they recognize this evidence was of a low quality.42 Moreover, since sutures have been in
used for longer than any other closure technique they have accumulated the largest
Despite their wide acceptance, sutures are associated with very long procedures times,
requiring the surgeons a high level of training and expertise. As a consequence, the
suturing success rates greatly depends on the surgeon ability and knowledge, varying
from one to another.13,14,16,19 Another user-dependent outcome is related to the accuracy
of positioning the stitches; a major issue when operating in reduced spaces during
laparoscopic and robotic surgeries.1
In plastic surgeries, cosmetic outcomes are of key importance, and the scar tissue
formation around a closed wound could have negative effects on aesthetics. While in
internal applications aesthetics is not a decisive factor, an exacerbated fibrous scar tissue
formation may negatively influence the normal function of organs and tissues by limiting
motion and elasticity, creating stress concentrations areas, restricting permeability,
electrical conductibility, or absorption properties, just to mention a few consequences.58
This prejudicial fibrous tissue can easily be formed due to excessive tightness or incorrect
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suture positioning.65 In addition, sutures are less than optimal when a fluid-tight closure
is needed,24,51 for instance in vascular and other hollow organs anastomoses, and in lung
and dural closures.11 Among the other most commonly cited downsides of sutures are the
need of anesthesia, nerve damage, inflammatory reactions, and granuloma formation.16
Staples and clips, other mechanical fasteners, are said to be faster methods when
compared to sutures.4 Some authors associates staples with higher infection rates than
sutures,66 while others have concluded that staples are associated with fewer infection
occurrencies.16,67 While not conclusive and most likely depending on the specific
application, infection is a major complication that must be avoided or mitigated at all
costs. Staples comes in a variety of materials, permanent or absorbable, and also share
with sutures the intrinsic limitation of creating tissue trauma by its mechanism of action,
piercing the tissue and generating small ischemic areas around their track.34 Table 1.3
summarizes the pros and cons of mechanical fasteners and tissue adhesives.

1.3.2 BIOLOGICALLY DERIVED MATERIALS
The attractiveness of using naturally occurring materials lies on their inherent
biodegradability that allows for good biocompatibility, which in general terms is better
than synthetic materials.14,59 This is explained by the origin of most of these products;
namely human or animal derived proteins, and polysaccharides that can be found in either
humans, animals, invertebrates and insects, resembling natural molecules in our body.
Fibrin and collagen based adhesives are the best known representatives of this group due
to their general acceptance in many medical specialties,14 though fibrin-based materials
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are irrefutably the principal biological sealant systems in clinical use.38 An average of
200 articles published every year, investigating fibrin-based materials for adhesive and
sealant uses, reflects the high interest that surgeons and industry have been showing on
these products.15
In 1998, fibrin was approved as a hemostat by FDA, and since then it is the only
material that would be cleared for intended uses as hemostat, sealant and adhesive.68
Current on-label indications of fibrin products approved by FDA include colon sealing as
a sealant, skin graft at burn debridement sites as a replacement for sutures or staples and
facial flap attachment at the time of rhytidectomy as an adhesive, and in all types of
surgeries as an hemostat.15 Off-label use of fibrin greatly exceeds these indications.
Fibrin-based products act by reproducing the final steps of the blood coagulation
cascade, thus producing a fibrin clot on the surface of the wounded tissue.38 The fibrin
glue, as it is widely known, typically comes in the form of two separate subproducts,
fibrinogen (frequently with factor XIII) and thrombin with calcium chloride.69 Whilst
fibrinogen is always derived from human plasma, thrombin can also be extracted from
bovine blood. When these two components are mixed together, thrombin cleaves the
fibrinogen creating fibrin monomers that eventually forms a fibrin polymer. From here
on, the process resembles exactly the blood clot formation to form an insoluble clot that
will kept together through fibrin polymer crosslinking and by interactions with the
surrounding tissue proteins. Many commercially available formulations contain an antifibrinolytic agent, such as bovine aprotinin, to stabilize the resulting network and extend
its lifetime.70 Fibrin delivery methods very according to specific applications, and due to
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the physical state of the product. It can be apply with the help of a syringe or spray when
it is used in a liquid or foamy8 state. Also, dry fibrin sealants are available, produced
from the same base materials that are lyophilized and packed on a backing material.14
According to Duarte, despite the fact that fibrin is the most widely used material after
mechanical fasteners, and show good results for specific applications, at least three
limitations are preventing them from taking off as a serious alternative to sutures. First,
their tensile and adhesives strengths are not appropriate to withstand large mechanical
loads. Second, because they are derived from human or animal plasma, the raw materials
are not always readily available. The costs are also impacted by their reduced availability
compared to synthetic materials, making these products more expensive. Finally, and also
due to its animal origin, the fibrin products might transmit viral diseases if not screened
properly.14 However, virus-inactivated fibrin glues are being developed and the potential
for virus transmission is managed to remain extremely low.54 In addition, since fibrin
products are protein-based, they can also be pro-inflammatory, producing hypersensitive
reactions in certain patients.11
Collagen-based materials also use the adhesives properties of a blood clot to create
hemostats and sealants. Collagen can provide a matrix that traps blood and coagulation
factors, while its surface can promote platelet aggregation, thus creating a favorable
environment for the blood clot creation.71–73 Spotnitz classifies these type of hemostats as
mechanical, since they act by creating a mechanical barrier to blood flow as well as a
scaffold for clot formation.61 These collagen systems frequently incorporates thrombin,
fibrinogen, and other coagulations factors to further enhance the blood clot formation.74

14

They share the same type of limitations with the fibrin-based materials, although it has to
be mentioned that swelling could be another issue with collagen matrixes.14 On the other
hand, collagen-based hemostats are less expensive than their fibrin counterparts.75,76
Collagen can also be produced in the form of gelatin, which is obtained by its
denaturation and hydrolysis, but keeping he same typical amino acid sequences.77
Therefore, gelatin can be subjected to many of the crosslinking methods of protein-based
materials to form tissue adhesives. The best known examples of these materials are the
Gelatin-Resorcinol-Formaldehyde (GRF) and Gelatin-Resorcinol-FormaldehydeGlutaraldehyde (GRFG) systems, where the formaldehyde and glutaraldehyde are used to
crosslink the gelatin and resorcinol. These crosslinking agents have accumulated a
significant evidence of toxicity, what has promoted others crosslinking mechanisms to be
investigated.16 GRF tissue adhesives are currently used in Japan and Europe to treat aortic
dissections. In the United States these glues have not been approved yet, due to concerns
about possible toxicity and carcinogenicity of formaldehyde.38 To avoid the use of
potentially hazardous crosslinking, researchers have investigated alternatives crosslinking
methods to be paired with gelatin-based products. Some examples of these methods are
the use of enzymes,14 genipin, disuccinimidyl tartrate (DST), SS-PEG-SS (succinimidyl
succinate ester of PEG),16 or two dialdehydes (currently commercialized in Europe).38
Another protein-based material similar to the GRFG adhesives is BioGlue (CryoLife). It
consists of bovine serum albumin and gluteraldheyde. The latter covalently crosslinks the
protein domains within 20 to 30 seconds and reaches its bonding strength in 2 minutes.78
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The last important group of naturally derived tissue adhesives is formed by
polysaccharides, found in animal, invertebrates and plants. These glues consist of
functionalized polysaccharide units, that includes chitin/chitosan, dextran, chondroitin
sulfate, hyaluronic acid and alginate.12,14,38 These biopolymers are based on naturally
occurring sugar blocks, therefore fully biodegradability and biocompatibility should be
easier to achieved when compared with synthetic polymers.12 Polysaccharides have also
been associated with antimicrobial functions, making them also attractive to fight
bacterial infections.12,79 In addition, polysaccharides have been early recognized by their
potent hemostatic capabilities. That is why most of polysaccharide-based products in the
market aims to stop bleeding as their primary function.1 In general terms, polysaccharides
are biodegradable, biocompatible and do not elicit immune or histotoxic reactions.
However, these materials exhibit poor solubility in water, high degradability patterns, and
they do not promote tissue adhesion naturally, thus needing the introduction of reactive
species into their original chains.12 Sanders et al., have incorporated chitosan to a
Tetronic-based tissue adhesive under investigation to couple the thermogelling and good
adhesive characteristics of functionalized Tetronics and the superior hemostatic features
of the polysaccharide, obtaining promising results.4
Chitin and chitosan promotes blood coagulation because of their net positive charge
that attracts red blood cells, thus promoting the formation of blood clots even in the
absence of platelets or coagulation factors. These polysaccharides are mainly extracted
from the exoskeleton of invertebrates, and are also found in the cell wall of fungi. As all
other polysaccharides, chitin and chitosan are biocompatible and biodegradable
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substances, though they show poor water solubility due to the creation of crystal
structures.12 This poses a challenge for industrial fabrication, justifying the need for more
soluble alternatives. Ishihara and coworkers, enhanced chitosan solubility in water by
introducing lactose moieties into it.80
Another polysaccharide of interest is alginate, an anionic polysaccharide found in
brown algae. These aquatic forms of life use a mechanism of adhesion based on this
polysaccharide that have interested some researchers because it can function under
water.14 To mimic this interesting behavior, alginate monomers have been combined with
calcium ions and phloroglucinol to crosslink the building blocks.81
Dextran, which is an exocellular bacterial polysaccharide, can be oxidize to form a
dialdehyde-dextran compound. The resulting product can react with amine groups,
acquiring bioadhesive properties.33 Modified dextran monomers have be conjugated with
PEGs and chitosan to provide a more effective hydrogel network, higher degradation
times, and higher adhesive strengths.14,33
Glycosaminoglycans (GAGs) are a distinctive constituent of cartilage and other
tissues, and because of their natural presence in our body they have been evaluated as
tissue adhesive products. The use of GAGs as bioadhesvies has been explored by the use
of chondroitin sulfate (CS) and hyaluronic acid (HA). Both CS and HA need to
incorporate reactive groups such as aldehyde and acrylates to acquire adhesive properties,
due to the lack of inherent adhesive properties.12,14
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1.3.3 SYNTHETIC TISSUE ADHESIVES
The most important members of the synthetic family are polycyanoacrylates,
polymeric hydrogels, and polyurethanes. A four commonly described group comprises of
hyperbranched and dendritic polymers.

1.3.3.1 Cyanoacrylates
Polycyanoacrylates are probably the most popular and most used synthetic tissue
adhesive, though their applications are almost restricted to topical use.33 Cyanoacrylate
monomers are liquid and can quickly react in the presence of weak anionic substances,
such as water or blood. Once the monomers are exposed to the anionic substances, the
acrylates are turned into active radicals and react very fast through anionic
polymerization.39 There is no need for a catalyst, heat or pressure to start and maintain
the polymerization. Before complete polymerization, the liquid monomers penetrate the
surface irregularities and adhere to the surrounding tissues by two mechanisms; covalent
crosslinking with proteins functional groups, and by mechanical interlocking with the
tissue cracks and channels through which it has flown.12,33
The mechanical properties of polycyanoacrylates are highly dependent on the length
of the alkyl side chain. Shorter chains give stronger networks, while longer chains allow
for higher flexibility (flexible bonds). The overall braking strength is achieved with
longer chains that forms more flexible polymeric networks.12,39 For instance, butyl
cyanoacrylate would give stronger bonds than octyl cyanoacrylates, but since the latter
create more flexible linkages, the overall failure resistance would be higher in the octyl-
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cyanoacrylate polymer. In average, all cyanoacrylates are too brittle to be used in long
wounds, or in places where the glue is subjected to cyclic load, e.g. on a skin fold over a
joint and fails in provide a good adhesive performance in zones of dense hair.33,61
Shorter alkyl chains will produce polymers that degrade faster than those made with
longer side chains. A byproduct of cyanoacrylates’ degradation is the histotoxic
formaldehyde. This is why methyl- and ethyl-cyanoacrylates are currently not an option
for medical applications. Consequently, longer chains are preferred to delay or prevent
degradation from happening. For instance, by the time that degradation of 2-octylcyanoacralate would start to produce cytotoxic compounds, the material is most likely to
have already been flaked off the skin (7-10 days), avoiding their noxious effects.12,33,39,76
All in all, cyanoacrylates are a good choice for small-sized superficial wounds. They
are easy to use, polymerize quickly and do not need additives or further chemical
modifications, do a fair job from a cosmetic perspective, and are much stronger than
biological products. The list of disadvantages is also numerous, and includes, but is not
limited to, potential toxic effects, poor mechanical performance in large wounds, skin
folds, hairy areas, migration to unwanted areas when applying the material, risk of
allergy, and the price tag is relatively higher than other alternatives for topical wound
treatment. But far more important is the fact that cyanoacrylates have been associated
with serious toxic effects when used internally, and therefore no product has been cleared
as a tissue adhesive for that type of use. Omnex™ (Ethicon) has been the first product
based on cyanoacrylates that was approved by FDA (in 2010) for internal use as sealant
to prevent leaks around sutures in vascular reconstructions,82 though it has been also
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tested for other applications, such as a colonic sealant.83 This product has been designed
to degrade slowly, over 36 months, so the release of formaldehyde is kept within safety
limits.61

1.3.3.2 Polymeric hydrogels
While cyanoacrylates are the first for skin closure, polymeric hydrogels are the most
studied systems for internal applications. Hydrogels are crosslinked polymer networks
that due to their hydrophilic nature can absorb large quantities of water,84 and hold
together as water-swollen structures.85 Despite the fact that many polymers are good
candidates to form hydrogels systems, PEG-derived materials have been the most
extensively investigated for this type of uses, and are currently present in numerous
marketed devices.
PEG is neutral, biocompatible, inert (does not elicit an immune response), watersoluble, biodegradable, and can be prepared over a wide range of molecular weights,
shapes, and with a variety of end groups.33 These characteristics make PEG a good
candidate for biomedical applications, and in particular for tissue adhesive creation. Since
PEG does not react with tissue components is not able to establish adhesive interactions
with them, and needs to be grafted with reactive groups to acquire adhesive properties.33
Although it is associated with highly desired characteristics, it is also necessary to
recognize some disadvantages. When used as a tissue adhesive, it requires innovative
solutions to avoid problems. PEG structures normally swell considerably, offer short
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handling times due to fast crosslinking, exhibit low bulk strength and high degradation
rates, and some authors mention cost as another downside.12,14,33,39
FDA has approved several PEG-based products in three different groups:
photopolymerizable adhesives, PEG-trilysine adhesives, and adhesives based on two
differently functionalized PEG polymers.12 FocalSeal® (Focal, Inc. / Genzyme) is an
example of photopolymerizable tissue adhesive. It consists of two different ABA block
copolymers with PEG as the central unit, and acrylates end groups. The crosslinking
occurs between the acrylates when the substances are irradiated with light of 470-520 nm
in the presence of a photoinitiator.12 FocalSeal-L has proven to be effective in sealing air
leaks during major thoracic surgeries, although it takes quite a long time to be prepared,
applied and set, reducing considerably its usability and applicability.14 In 2003, due to
several factors including manufacturing costs, slow adoption and a change in the
company business plan, FocalSeal was withdrawn from the market.86
DuraSeal® (Integra LifeSciences) belongs to the second category of PEG adhesives,
the PEG-trilysine materials. This product that is indicated as an adjunct to sutures to
create a water-proof seal on dural repairs consists of two liquid solutions: a trilysine
amine solution and a PEG-NHS solution, which react upon mixing to create an hydrogel
in 3 s.16 DuraSeal establishes covalent linkages with tissue amines and their NHS esters.
The third group of PEG materials is formed by two differently functionalized PEGs,
having complementary reactivity to crosslink between each other. CoSeal® (Cohesion
Technologies / Baxter) is composed of two 4-arm PEGs, one end capped with thiol
groups and the other one with NHS groups. Upon mixing the two PEGs form thioester
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linkages between the two functional groups.39 Both unreacted NHS and thiols can also
create covalent bonds with tissue protein residues, but the main mechanisms of tissue
adherence is between protein amines and the thioesters in the hydrogel network.12

1.3.3.3 Polyurethanes
In the search for biocompatible new materials to create stronger tissue adhesives,
polyurethanes have been also recently investigated. These materials are fabricated by the
polyaddition of isocyanates and dials/polydiols.39 When used as adhesives, these
materials usually come as prepolymers with highly reactive isocyanates end groups that
react with water (or other hydroxyl-containing compounds) to form a polymer network
and with protein amines to create adherence to the underlying tissues.33 TissuGlu®
(Cohera Medical) is a lysine-derived polyurethane-based adhesive that has had CE mark
since 2011, and has recently been approve by the FDA in 2015.87 This one-component
glue consists of a isocyanate-terminated hyperbranched polymer, containing lysine
residues.12 TissuGlu Surgical Adhesive is indicated for the approximation of tissue layers
where subcutaneous dead spaces exists between the tissue planes in abdominoplasty,88 to
prevent these dead space from build up fluids and develop seromas.33 Polyurethane
adhesives are still facing some important challenges such as their prolonged curing time,
biodegrability of some ether-based polyurethanes, and toxicity and carcinogenicity of
degradation products.39
A final group of synthetic polymers used in tissue adhesive developments are
hyperbranched and dendrimers. The rationale behind the use of these polymers is the high
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number of functional groups they can carry in their numerous branches.1 A large number
of functional groups could lead for instance to high crosslinking densities, making these
macromeres attractive to achieve increased bulk and adhesive strengths, as well as tuning
degradations rates.

1.3.4 OTHER APPROACHES
Adhesives tapes are a hybrid device of mechanical fastener and adhesive that plays an
important role in day-to-day operations in emergency and operating rooms, though their
use in internal organs is not prescribed. However, the concept of a tissue adhesive
supported by a tape or patch is a valid research route that some investigators have already
taken. A different approach to close a wound is to reconnect the disrupted extracellular
matrix proteins by focusing a laser beam on the tissue under repair. This technique has
shown promising results on thin or single layer skin so far.4
Many researchers are studying how nature solves problems of adherence in an
attempt to incorporate biomimetic concepts into the tissue adhesive designs. The most
studied natural adhesive phenomenon is the one involving mussels adhering strongly to
virtually any material under water. The proteins that help the mussels get these
extraordinary adhesive properties have been identified, though their extraction has proven
difficult in resulted in extremely low yields.12 Genetically engineered proteins also
resulted in low yields.12 Therefore, investigations have targeted synthetic moieties to
simulate the action of these adhesives proteins rich in lysine and tyrosine, which is posttranslationally modified to L-3,4-dihydroxyphenilalanine (DOPA).39 DOPA and DOPA-
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like residues have been grafted to a variety of polymers to mimic mussels’ stickiness with
promising results in terms of adhesive and bulk strengths, and the ability to control them.
Another nature-inspired strategy to achieve adhesive materials is to mimic the
characteristics of geckos’ feet. Geckos can walk, run and climb inverted surfaces thanks
to millions of microscopic hairs that cover the surface of their soles. At this sub-micron
scale, capillary forces and van der Waals interactions are the most relevant attractive
forces for hydrophilic and hydrophobic materials, respectively.39 Attempts to emulate
these properties have been carried out by designing micro patterns of repetitive tiny
pillars on a substrate material. These systems completely lose adherence when immerse
in water. Many ideas have been tested to overcame this problem, such as coating the
micro pillars with mussel-inspired compounds to add chemical interactions with the
surface to be glued.12 A second line of research on the physical micro scale is based on
endoparasitic worms, that use their proboscis to penetrate through the tissue and keep in
place by expanding the tip of these microneedles.12 Artificial arrays of microneedles have
been prepared and tested as adhesive materials, incorporating different features such as
tip coating with swellable polymers to recreate the proboscis expansion strategy, or
creating barbed microneedles to augment the pull-out force from the tissue.24
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Table 1.2 Wound closure methods and examples, including adhesives, sealants, and hemostats.
Category
Mechanical
fasteners

Subtypes

Materials (Example of products and companies)

Sutures, wires,
stapes, clips

• Absorbable: catgut, polyglycolic acid, polydioxanone,
polytrimethylene carbonate
• Non-absorbable or permanent: silk, nylon, polypropylene,
polyester, polybutester
• Fibrin: Tiseel® and TachoSil® (Baxter); Evicel® and Evarrest
(Ethicon); Vitagel (Stryker, combines collagen, thrombin,
fibrinogen and platelets); Cryoseal (Thermogenesis)
• Thrombin: Evithrom® (Ethicon); Recothrom
(Zymogenetics/BMS); Thrombin-JMI (King/Pfizer)
• Collagen / gelatin: FloSeal (Baxter, combines gelatin and
thrombin); CoStasis (Cohesion Technologies); Proceed® (Fusion
Medical); Helistat and Helitene (Integra); Instat and Ultrafoam
(Ethicon); Gelfoam (Pharmacia); SurgiFoam and SurgiFlo
(Ethicon); Avitene (Bard)
• Albumin: ArterX® (Tenaxis Medical); BioGlue (Cryolife)
• Chitosan: HemCon (HemCon Medical Technologies); Celox
(Medtrade Products); QuickClot (Z-Medica)
• Cellulose: Surgicel (Ethicon)
• Dextran: See semisynthetic materials
• Chondroitin sulfate: functionalized with aldehyde and acrylates
(not marketed)
• n-Butyl-2-cyanoacrylate: Indermil® (Covidien / Medtronic);
Histoacryl® and Histoacryl Blue® (Tissue Seal); LiquiBand®
(Advance Medical Solutions)
• n-Butyl-2-cyanoacrylate/methacryloxysulpholane: Glubran2®
(GEN SRL)
• 2-Octyl-2-cyanoacrylate: Dermabond® (Ethicon); SurgiSeal®
(Adhezion Biomedical); Liquiband Flex® (Advance Medial
Solutions); Octyl Seal (Medline Industries)
• n-Hexyl-2-cyanoacrylate: IFABond® (IFA Medical)
• n-octyl-2-cyanoacrylate+butyl lactoyl-2-cyanoacryalte:
Ommex® (Ethicon)
• PEG-co-poly(lactic acid)/poly(trimethylene carbonate:
FocalSeal® (Focal, Inc. / Genzyme)
• PEG-NHS + trilysine: DuraSeal® (Integra LifeSciences)
• PEG-NHS + PEG-thiol: CoSeal® (Cohesion Technologies /
Baxter)
• PEG-NHS + PEG-amine: SprayGel (Confluent Surgical /
Covidien)
• Lysine-derive urethane: TissuGlu (Cohera Medical).
• PEG-NHS + Albumin: ProGel (NeoMend)
• Dextran Aldehyde + PEG-amine functionalized with tris(2aminoethyl)amine: Actamax (DMS-DuPont)
• Adhesive tapes
• Laser welding
• Biomimetic adhesives (under evaluation): mussel-, gecko-, and
endoparasitic-worm-inspired adhesives.

Protein-based

Biologically
derived
materials
Polysaccharidebased

Cyanoacrylates

Synthetic
polymers
Polymeric
hydrogels

Urethane-based
Semisynthetic
materials

Other approaches
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Table 1.3 Strengths and weaknesses of wound closure groups.
Category

Strengths

Weaknesses

Mechanical fasteners

• Tensile and pull-out strength
• Good tissue approximation to
promote wound healing
• Can be used in wet environments
• Variety of materials and
geometries for specific
applications
• Variety of applicators and tools
developed for their use
• Broad clinical data from an
extensive and sustained use
• Availability and cost

Biologically derived
materials

• Highest clinical evidence among
tissue adhesive and sealants
• Good sealants
• High biocompatibility

Synthetic polymer

• Properties can be easily tuned
• High bulk and adhesive strengths
• Overall good biocompatibility,
except some exceptions
• Virus-free
• Availability, scalability, costs

• Time consuming (staples are faster
than sutures)
• Need for anesthesia
• Not always technically possible
• Scar formation
• Tissue adhesions
• Inherently traumatic to tissues
• Risk of nerve and vessels damage
• Fluid leakage through needle holes
• Fluid leakage through closure line
• Fluid-leak-related tissue reactions
• Material related tissue reactions
• Risk of viral transmission
• Risk of hypersensitive reactions
• Poor adhesive and bulk strengths
• Some are expensive and not
readily available
• Significant swelling (PEGs)
• Allergenicity, toxicity,
carcinogenicity
• Clinical evidence is scarce: only
one urethane-based adhesive
approved by FDA for internal use
(TissueGlu®) and one
cyanoacrylate sealant (Omnex®)

1.4 A brief review on Tetronic-based adhesives
To address the issues associated with the current biological and synthetic tissue
adhesives, researchers have been exploring Tetronic® (BASF) as a base polymer for a
novel wound closure device.46,59,89 Tetronics are synthetic polymers that have found
many biomedical applications due to their ability to form useful hydrogels. The
properties of these hydrogels systems can be tuned by introducing modifications on the
chemical structures and controlling the physicochemical interactions of the polymers.
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1.4.1 GENERAL DESCRIPTION OF TETRONICS
Tetronic or poloxamines are 4-arm, amphiphilic block copolymers, with a central
ethylene diamine that binds the 4 arms. Each arm consist of an A-B block copolymer of
polypropylene oxide (PPO: A) and polyethylene oxide (PEO: B).5 Tetronic R® are
similar to Tetronic, but has an inverted block order, with the PEO in the core, and the
PPO as the end segments. Pluronic® (BASF) or poloxamer are frequently studied
together with Tetronic since are formed with the same building blocks. Pluronics are
linear triblock copolymers (A-B-A), with a central PPO trapped between two PEO blocks
(Figure 1.1). Pluronics and Tetronics are two big families of surfactants with different
physical and chemical properties that are in use or under investigations as wetting,
dispersant, and thickener agents and as emulsifiers90 but also as part of medical devices in
gene delivery therapies, tissue engineering, tissue adhesives, among others.4

Figure 1.1 Pluronic (A) and Tetronic (B) structures (T304: n=3.8, m=4.3; T1107: n=60, m=19).
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Tetronics are named with a numerical code that is based on their chemical structure.
In this code, the last digit multiplied by 10 represents the weight percent of EO units, and
the first two digits multiplied by 100 result in an approximation of the PPO molecular
weight of each block.91 When the numeric code only consists of three digits (e.g. T304),
the very first one is used to calculate the PPO block molecular weight. For Pluronics, the
code includes an initial letter that indicates their physical state at room temperature, F for
“flake” (solid), L for liquid and P for paste. The last digit of the code approximates the
weight percentage of EO when multiplied by 10, and the first one or two digits define en
estimate of the molecular mass of the PO block when multiplied by 300.92 Table 1.4
summarizes the most important compositional parameters of several Pluronics and
Tetronics, revealing the relationship between these parameters and the identification
code.

1.4.2 THERMAL GELATION IN TETRONICS
Tetronics, and Pluronics as well, are examples of thermoresponsive polymers,
meaning they can change at least one of their properties when subjected to a change in
temperature. When in aqueous solutions, these polymers can undergo a gelation process
just by increasing the temperature of the solution, process known as thermal gelation.93
Gelation occurs in these systems due to a temperature-induced phase transition, which in
most cases is reversible when the temperature is restored.94 These types of
thermoresponsive polymers are widely known as LCST polymers, for Low Critical
Solution Temperature; below this temperature threshold, these polymers are soluble, but
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above it they become insoluble. Most of thermoresponsive polymeric hydrogels used in
biomedical applications are LCST, i.e. those that gel upon heating, being poly(Nisopropylacrylamide) (PNIPAAm) the first described and most commonly found in
literature as example of LCST gels.47,85,95 Other polymer solutions behave in the opposite
direction. They need to be cooled down to become insoluble and form the gel. In this
case, the threshold temperature is known as Upper Critical Solution Temperature
(UCST).47,96

Table 1.4 Compositional characteristics of some Tetronics and Pluronics. Adapted from
Chiappetta et al.97
Total
average
number of
EO units

Total
average
number of
PO units

Pluronics (poloxamers)
L42
1,630
L122
5,000
P85
4,600
P104
5,900
P105
6,500
P123
5,750
F38
4,600
F88
11,400
F108
14,600
F127
12,600

7.4
22.2
52.3
53.6
73.9
39.2
83.6
207.3
265.5
200.5

Tetronics (poloxamines)
T304
1,650
T704
5,500
T904
6,700
T1107
15,000
T1301
6,800
T1307
18,000

15.0
50.0
60.9
238.6
15.5
286.4

Polymer

MW (Da)

#EO /
#PO

Total
weight of
EO units
(Da)

Total
weight of
PO units
(Da)

PEO
weight
/ PPO
weight

PEO
weight /
Polymer
weight

22.5
69.0
39.7
61.0
56.0
69.4
15.9
39.3
50.3
65.2

0.33
0.32
1.32
0.88
1.32
0.56
5.26
5.27
5.28
3.08

325
1,000
2,300
2,360
3,250
1,725
3,680
9,120
11,680
8,820

1,305
4,000
2,300
3,540
3,250
4,025
920
2,280
2,920
3,780

0.25
0.25
1.00
0.67
1.00
0.43
4.00
4.00
4.00
2.33

0.2
0.2
0.5
0.4
0.5
0.3
0.8
0.8
0.8
0.7

17.1
56.9
69.3
77.6
105.5
93.1

0.88
0.88
0.88
3.07
0.15
3.08

660
2,200
2,680
10,500
680
12,600

990
3,300
4,020
4,500
6,120
5,400

0.67
0.67
0.67
2.33
0.11
2.33

0.4
0.4
0.4
0.7
0.1
0.7
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Figure 1.2 LCST polymers behavior. Below LCST polymer is soluble, and above LCST they
form a two-phase system.

For tissue adhesives, thermal gelation is a desired feature, since these materials can be
delivered in a liquid state using a syringe-like applicator, spread over the surface of
tissues, and only gel when warm tissues heat them up, meeting also the definition of insitu forming gels.47 The gel can easily remain in place around the wound, whereas liquids
are difficult to keep immobilized and can wash off from the site of application. On the
other hand, it is nearly impossible for a solid-like material to penetrate the cracks and
channels of tissue surface to increase the contact area between tissue and material. Also,
delivering a gel is more challenging because of their augmented flow resistance, and this
could be a significant issue when designing the instruments to deliver the adhesive,
especially in robotic and laparoscopic surgeries, through small diameter lines.
The first requirement of these thermoresponsive systems is that they must gel below
body temperature, otherwise gelation is not achieved at physiological conditions. In
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addition, there is an inferior limit for the gelation to happen. The ideal product should be
handled in the operating room without the risk of unintentional gelation within the
applicator or storage container. Thus, the gelation temperature should be set above room
temperature. With such a requirement, the usability of the product is also improved in
terms of storage and transportation conditions.
Gelation of thermoresponsive polymers is actually a phenomenon observed when
they are dissolved in aqueous solutions. Therefore, solubility is the key variable when
describing gels formation. The nature of polymer-polymer, polymer-solvent and solventsolvent interactions play a central role in determining gels properties. In general terms,
the solubility shift because of temperature changes is mainly due to variations in the
overall hydrophilicity/hydrophobicity ratio of the polymer chains.47 Schild has attributed
this behavior to complexes combinations of H-bonds and hydrophobic effects for the well
studied PNIPAAm systems;98 though is still a matter of debate to what extent each one
contribute to the LCST effect, if both are actually present.95
Gelation temperatures can be influenced by various factors. In his review article,
Chiappetta defines that micellization of Pluronics and Tetronics in water depends on
compositional parameters and environmental features.97 Micellization is a particular form
of aggregation, or gelation exhibited by these copolymers, characterized by the formation
of micellar structures. It is possible to define several composition parameters that show
direct impact on gelation temperatures such as molecular weight, hydrophilic/lipophilic
balance (HLB), and molecular architecture (pending groups, branching, end group
chemistry). Among the most commonly mentioned environmental factors altering the
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transition temperatures are pH, ionic strength, presence of small organic molecules (e.g.
drugs, proteins, salts) and polymer concentration
The micellization of PEO-PPO block copolymers is an entropically driven process that
is a function of the PPO block. The entropy increase upon heating is due to the release of
the ordered water molecules around the hydrophobic PPO units. Therefore, the ratio of
EO/PO units is crucial in determining the micellization temperature. The higher the PEO
(hydrophilic) content relative to PPO content, the higher the transition temperature.97
When the PPO content is reduced, the availability of hydrophobic regions is reduced, so
the entropy difference between the solution and micelle formation drops. If the entropy
difference is diminished, an increase in temperature needs to be delivered in order to get
the required negative Gibbs free energy of micellization. Wanka et al., working with
PEO-PPO copolymers, verified a decrease in critical micellization temperature when the
(hydrophobic) PPO content was increased.99
A great source to explore transition temperature dependence on different variables is
the article published by Alxandridis in 1994. His group worked with different Pluronic®
triblock copolymers, and they assessed their critical micellization temperature as a
function of different parameters.100 For all tested polymers, the critical temperature
shifted towards lower values when the concentration was increased. In addition,
comparing the critical temperatures of P85 and F88 at same concentration levels can
reveal the impact of HLB. P85 and F88 have almost the same number of PO units, but the
latter has much more EO (hydrophilic) units. The transition temperatures for F88 are
always higher than those for P85, at the same concentration levels.
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Lutz evaluated non-linear PEG molecules and concluded that depending on molecular
structure of their monomer units, these non linear chains can be either insoluble in water,
readily soluble or thermoresponsive.101 He studied graft structures composed of a carboncarbon backbone, provided by methacrylates with multiple oligo(ethylene glycol) side
chains. The increase in size of the hydrophilic side chains resulted in higher LCST.

1.4.3 TETRONIC-BASED TISSUE ADHESIVES
The reversible thermogelation exhibited by Tetronics, can be coupled with a covalent
crosslinking of the monomers to get a more stable and resistant permanent network, in a
process known as “tandem gelation”.49 Cho et al., characterized different blends of
acrylated Tetronics (T904 and T1107) as tissue adhesives using the tandem gelation
approach, with thiol donor molecules to act as crosslinkers.59 They hypothesized that
Tetronic adhesives bond to tissue through mechanical interdigitation with tissue
topographical defects, as well as by establishing chemical linkages to free thiols found in
extracellular matrix proteins. A comparison between these Tetronic-based adhesives and
a control PEG-based adhesive showed that the first group had a much better adhesive
strength in lap shear tests as well as significantly lower swelling behavior. Based on these
results, Balakrishnan investigated the possibility of increasing the cohesive strength of
Tetronic-based adhesives by blending a lower molecular weight polymer of the same
family, the T304 (MW = 1650 Da). By working with a smaller monomer, the ability to
incorporate more polymer in solution at the same polymer concentration, would give
place to an increase crosslinking density favoring a higher bulk strength. Results
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confirmed this hypothesis and, as a complementary result, a significant rise in the
gelation temperature was seen as the content of T304 (the lower MW Tetronic) was
increased.
Barret and coworkers investigated a biomimetic approach using functionalized T1107
as the based material for their hydrogel adhesive.89 The functionalization consisted in
modifying terminal groups of T1107 for 3,4-dihydroxy-L-phenylalanine (DOPA), that is
found in great quantities in the adhesive proteins of mussels. To crosslink the DOPAcontaining T1107, they would expose the material to a periodate (IO4-) solution to oxidize
the catechols to the reactive o-quinones that are able to chemically bind to cathechols,
amines, thiols, imidazols, etc.89 These adhesive materials showed interesting adhesion
strength levels in lap shear tests, higher than Cho’s59, although comparisons should be
approached with caution since the methods used by these authors are not identical. PEGbased hydrogels normally swell considerably, augmenting their volumes many times in
some cases. Barret et al., claim that with an “inverse” tandem gelation they created a
negative swelling material, a material that could virtually shrink once it is applied. The
inverse tandem gelation is achieved by generating the chemical crosslinking before the
thermally-induced gelation, in opposition to the traditional tandem gelation where the
thermally-induced gelation occurs first and the chemical crosslinking develops in a
subsequent step.
Sanders et al., functionalized T1107 with both acrylate and N-hydroxysuccinimide
(NHS) and by blending this bifunctional Tetronic with fully acrylated T1107 they have
achieved higher adhesive strength compared to both fully acrylated Tetronics, and DOPA
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containing Tetronics.46 The rationale behind adding NHS was to improve tissue bonding
through the interaction of NHS with amine residues, present in tissue proteins. These
research has identified a right balance of bifunctional T1107 and acrylated T1107 to
maximize the adhesive strength. However, this material exhibits a thermogelation below
room temperature, making its delivery very challenging. If not kept refrigerated all the
time, it could gel within the delivery system and clog the device. Therefore, a surgeon
would have a very limited time to manipulate and deliver the tissue adhesive before it
solidifies. Moreover, the adhesive should be liquid when making first contact with the
tissue to spread out easily and maximize the contact area with the microstructure of the
underlying tissue, something that would be significantly compromised if delivered in the
gel form. In addition, this material relies on hydrolysable linkages to create the covalent
network, and has shown relatively high degradation rates. In in-vitro experiments, this
material showed a degradation rate that would mean its disappearance before the treated
wound could heal and recover its mechanical strength. Further research is needed to
improve these two properties to make the Tetronic based material a strong candidate for
tissue adhesive applications in soft tissues.
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CHAPTER TWO
RATIONALE AND SPECIFIC AIMS
Sutures remain to be the most common wound closure method despite a long list of
limitations especially for expandable organs such as the urinary bladder and the lungs.
The reduction in surgical spaces with laparoscopic and robotic surgeries is calling for
innovation in wound closure methods where the classical mechanical ligatures are
proving very challenging, even for seasoned surgeons.1–3 Tissue adhesives have been
investigated as an alternative and/or adjuvant method to address some of these unmet
needs. Products based on biologically derived materials present their own set of
limitations, i.e. poor mechanical properties, risk of viral transmission or hypersensitive
reactions and from an industrial perspective, a difficult scalability. Adhesives made from
synthetic polymers are a promising group of materials that offer a good range of
possibilities to customize their properties, thus targeting specific needs such as adhesive
and bulk strength, degradation rates, and mechanical compliance. Aqueous solutions of
Tetronic polymers undergo reversible thermal gelation, which paired with a covalent
crosslinking leads to a tandem gelation process that make it appealing for adhesive
applications in the body.4 Previously in our lab, Sanders and co-workers4 developed a
successful adhesive by modifying Tetronic 1107 to incorporate acrylate (ACR) for
chemical crosslinking and N-hydroxisuccinimide (NHS) to enhance tissue bonding,
improving the seminal work done by Cho et al.5 The main goal of this master’s thesis
research is to further improve the performance of these Tetronic-based adhesives by
controlling the gelation temperature of these polymeric systems. Thermogelation mainly
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depends on polymer concentration, polymer size, and the ratio of hydrophobic to
hydrophilic segments. Consequently, we hypothesized that by introducing T304-ACR, a
smaller acrylated Tetronic, within the successful blends of modified T1107 published by
Sanders et al.,46 we could achieve an increased gelation temperature. Balakrishnan et al.,
developed preliminary tests on blends of unmodified T1107 and T304 to find a positive
relationship between the increments in gelation temperatures and the use of blends with
higher contents of T304.102 An increased gelation temperature would provide the user the
time to manipulate the adhesive without experiencing an unwanted gelation before it is
placed over the target site. To fulfill this goal, this research project has been divided into
the following aims:
Aim 1: To improve the acrylation efficiency of T304.
Rationale: Balakrishnan has previously attempted modification of T304 to be used in
tissue adhesives.102 However, the final product, the T304-ACR, exhibited low acrylation
conversions, resulting in adhesives with low effectiveness.
Approach: The critical steps in T304-ACR synthesis were identified and modified
one at a time to evaluate the impact of these changes. Final products were analyzed with
proton NMR to assess their compositional characteristics.
Aim 2: To evaluate the impact of incorporating T304-ACR on the gelation
temperature of Tetronic-based hydrogels.
Rationale: Thermal gelation temperature should be above room temperature to avoid
unwanted gelations before application and below body temperature to gel upon contact
with warm tissues. Tissue adhesives based on T1107, developed by Sanders et al.,4
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showed good adhesive performances, but they gel below room temperature. Tetronics’
gelation temperatures depend on several factors, being molecular size and hydrophilicliphophilic balance (HLB) among the most important. T304 is a member of the Tetronic
family with a lower molecular size and a different HLB resulting in increased gelation
temperatures.
Approach: The strategy to control gelation temperatures in modified-T1107-based
adhesives was to blend it with T304-ACR. Rheological studies were performed to
evaluate the impact of the addition of T304-ACR in different blends ratios and overall
polymer concentration on the gelation temperatures. Specifically, temperature sweep
experiments were run to find the temperatures at which the viscoelastic properties were
indicating a sol-gel transition.
Aim 3: To characterize critical adhesive properties after the addition of T304-ACR in
Tetronic-based adhesives.
Rationale: Although the original intent of the addition of T304-ACR was to control
the gelation temperature of these adhesive materials, other properties were expected to
change in the presence of this lower molecular weight Tetronic. We had previously
hypothesized that using T304-ACR in these hydrogel based adhesives could increase
bulk strength and stiffness, and decrease the degradation rates due to a higher
crosslinking density.
Approach: Adhesive strength was determined through lap shear testing, using
collagen sheet as substrates to mimic tissue proteins. The degradation profiles were
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characterized by analyzing the mass loss of adhesive samples that were incubated at
physiological conditions during different time periods.
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CHAPTER THREE
MATERIALS AND METHODS

3.1 Polymers functionalization (synthesis)
3.1.1 MATERIALS
Tetronic® 1107 (T1107, MW: 15 kDa, HLB: 18-23) and Tetronic® 304 (T304, MW:
1650 Da, HLB: 12-18) were donated by BASF corporation (USA). Acryloyl chloride,
Celite fine 500, 4-dimethylaminopyridine (DMAP), succinic anhydride, Nhydroxysuccinimide (NHS), 4-methoxyphenol (99%), calcium hydride, tetrahydrofuran
(THS) and chloroform were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Toluene (HPLC grade), diethyl ether (anhydrous, BHT stabilized), and anhydrous sodium
sulfate were purchased from Fisher Scientific (NJ, USA). Dichloromethane (DCM)
(HPLC grade), triethylamine (TEA), ditiothreitol (DTT), sodium bicarbonate, calcium
hydride and d-chloroform (CDCl3) were obtained from Across Organics (NJ, USA) and
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) from Tokyo
Chemical Industry (Tokyo, Japan). All other chemicals were used as received.

3.1.2 ACRYLATION OF T1107
The synthesis of T1107-ACR was carried out following previously published
methods.4,59 Succinctly, terminal hydroxyl groups in each of the four arms of T1107 was
reacted with acryloyl chloride to produce the acrylate end-capped T1107(Figure 3.1).
First, 30 g (2 mmol) of T1107 was dissolved in 300 mL toluene and dehydrated through
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azeotropic distillation. Then, the excess of toluene was removed by rotary evaporation
and the product was dissolved in 270 mL of dehydrated DCM (dried with calcium
hydride) and transfer to an ice bath. Next, 8 mmol of TEA was pipetted into the round
bottom reaction flask and 16 mmol of acryloyl chloride was then added dropwise (diluted
in 30 mL dried DCM). Reaction flask was kept in a cold room (4 ˚C) under continuous
stirring for 24 hr so the reaction could fully develop. After reaction was stopped, the
solution was filtered through Celite and paper-filter to remove TEA-HCL salt. DCM was
evaporated off from the filtered solution in a rotary evaporator and remaining product
was precipitated in 500 mL of cold diethyl ether, recovered by paper-filtration and
vacuum dried overnight. The day after, product was dissolved in 300 mL DCM and
underwent sequential washes with sodium bicarbonate (10%w/v) first, and then with
double deionized water (to remove the sodium bicarbonate). Traces of water were
eliminated using anhydrous sodium sulfate. Solution was concentrated again with a rotary
evaporator to remove DCM and the thick liquid that remains was precipitated in cold
diethyl ether (3 times) and recovered by filtration. Final product was vacuum dried for 48
hr and stored in a refrigerator at 4 ˚C. Proton NMR in d-chloroform was used to assess
the composition of T1107-ACR.

Figure 3.1 Reaction scheme for the acrylation of T1107 and T304. T: represents a Tetronic
molecule. Only the end EO unit from one arm is shown.
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3.1.3 NHS ADDITION TO T1107-ACR
NHS groups were attached to the unreacted arms of partially acrylated T1107 (50%
acrylated, i.e. 2 of 4 arms acrylated) (Figure 3.2). To prepare the 50% acrylated Tetronic,
the same protocol to make the fully acrylated T1107 was followed, but using different
reagents ratios; i.e. 1:2:3 of T1107 to TEA to acryloyl chloride. The unreacted hydroxyl
terminal groups were exchange for NHS moieties by a two-step reaction, where succinic
anhydride was first made to react with the hydroxyl groups, followed by the addition of
NHS. Briefly, T1107 partially acrylated (1 mmol), succinic anhydride (2 mmol) and
DMAP (0.1 mmol) were mixed and dissolved in 250 mL of THF. Reaction was allowed
to occur under nitrogen for at least 12 h. The obtained solution was concentrated in a
rotary evaporator and purified by precipitating it three times in cold diethyl ether. After
each ether wash, the product was recovered by centrifugation. The intermediate product
was vacuum dry overnight. Next step consists in dissolving this intermediate product
(T1107-ACR-COOH), NHS and EDC in a ratio of 1:2:2.5, respectively, in 250 mL of
THF. The reaction was developed under nitrogen for 4 h. Three cold ether washes were
performed and final product was vacuum dried for 48 hr before checking conversion
efficiency with proton NMR. T1107-ACR-NHS was stored in a sealed flask at 4 ˚C.
Proton NMR in d-chloroform was used to assess the composition of T1107-ACR-NHS.

Figure 3.2 Reaction scheme for the addition of NHS to an unmodified arm of a partially
acrylated T1107. T: represents a Tetronic molecule. Only the end EO unit from one arm is shown.
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3.1.4 ACRYLATION OF T304
The T304 acrylation reaction was similar to that for T1107-ACR (Figure 3).
However, due to differences in solubility, in physical properties (T304 is a thick liquid
whereas T1107 is solid) and in hydrophobicity, the purification steps had to be adjusted.
The molar ratios between T304, TEA and acryloyl chloride were kept unchanged (1:4:8),
and the solvents used in the azeotropic distillation as well as during the reaction were the
same (toluene, and dried DCM, respectively). Once the reaction was completed, and
solution was filtered through Celite and paper-filters to remove TEA-HCL salt, a rotary
evaporator was used to eliminate DCM, at room temperature and low vacuum. Then, the
T304-ACR was precipitated in a hexane/diethyl ether solution (1:1 in volume), and
finally the flask containing the mixture was placed in a -20 ˚C freezer for at least 6 hr.
Next step consisted of performing sodium bicarbonate and double deionized water
washes (as described in 3.1.2. Acrylation of T1107), and removing traces of water with
anhydrous sodium sulfate. DCM was evaporated off in a rotary evaporator at room
temperature and low vacuum, and the concentrated product was again precipitated in cold
hexane/ether and left in a freezer for at least 6 h. If precipitation occurred with ether
(before adding hexanes), a vacuum paper-filtration was carried out to remove the
crosslinked product. Then, the final product was vacuum-dried for 4-8 hr in a desiccator
kept on an ice bath. Proton NMR in d-chloroform was used to assess the composition of
synthesized T304-ACR, and NMR simulations were run to explore spectra of different
molecular architectures in MestReNova software, version 10.0.2-15465, with imported
MOL files created online.103
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3. 2 Preparation of hydrogels and adhesives
3.2.1 HYDROGELS
To make the thermoresponsive polymer solutions, the appropriate amount of each
modified Tetronic (T304-ACR, T1107-ACR, and T1107-ACR-NHS) was dissolved in 1x
PBS up to the desired polymer concentration. To promote a full dissolution, the mixtures
were left in a cold room under continuous shaking for 6-24 hr, depending on the polymer
concentration. After mixing in a cold environment, polymer solutions were kept
refrigerated, and in vials covered in Aluminum foil to avoid light exposure.
Transportation and handling before their use was done on ice baths to avoid unwanted
thermal gelation.

3.2.2 ADHESIVES
The adhesives used in these characterization experiments were made using polymer
solutions consisting of T304-ACR, T1107-ACR, and T1107-ACR-NHS. The chemical
crosslinking among the modified Tetronics was accomplished via a Michel-Type addition
reaction using DTT as the thiol donor crosslinker. Briefly, DTT solutions were prepared
fresh for each experiment at a concentration of 3 mg of DTT in 10 µL of PBS and kept on
refrigerator or ice bath until use. To make the adhesive solutions, polymer blend solutions
and DTT solutions were mixed at a thiol to acrylate molar ratio of 1:1, and vortexed for at
least 5 s before use.
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3. 3 Thermal gelation characterization
Thermogelation properties were assessed via rheological analysis using the AR1000
(TA Instruments, New Castle, DE). The gelation temperature was defined as the
temperature at which the storage moduli (G’) crosses over the loss moduli (G”) in a
temperature sweep experiment, at constant frequency (0.1 Hz) and constant strain (0.01).
This crossover point was defined indirectly. Since the crossover point of the two moduli
means that both values were identical, the angle formed by G’ and G” (delta) must be
equal to 45˚. Therefore, the gelation temperature was defined as the first temperature
value at which the delta angle was below 45˚. Specifically, the chosen geometry was 40mm stainless steel parallel plates, with an effective gap of 150 µm. Samples of the
polymer blend solutions (270 µL) were pipetted onto the lower plate at an initial
temperature of 4 ˚C, and temperature sweep was allowed to reach a maximum
temperature of 40 ˚C, in increments of 1 ˚C. This temperature range was representative of
the physiological internal temperatures, as well as low temperatures representative of
potential storage conditions.
Average G’, G”, delta and viscosity at physiological temperatures were obtained by
averaging the values at temperatures ranging from 35 ˚C to 39 ˚C to smooth down
individual peak values, specially found in viscosity readings. Delta is defined as the
phase angle of the complex shear modulus, and it is calculated as arctan(G”/G’).

45

3. 4 Adhesive strength characterization
The bond strength between Tetronic-based adhesives and tissues was measured
through a lap shear protocol that was previously developed in our research group.46 The
protocol, adapted from ASTM-F2255-05, consists of gluing the ends of two rectangular
collagen sheets on metal fixtures with the adhesive under evaluation and subjecting them
to a uniaxial load until the collagen sheets were fully separated (Figure 3.3). The
registered peak load, divided by the effective contact area, was calculated as bonding
strength or adhesive strength.

Figure 3.3 Schematic representation of a specimen used in the lap shear test.

The collagen sheets (DeWied International Inc., TX) were first soaked in 1x PBS for
1 h. Then, they were glued onto an aluminum sheet using regular cyanoacrylate adhesive
(superglue). After a curing period of 8-12 h, the ensemble was cut down to 4x1 cm strips,
and the hemi-specimens were soaked in PBS for 1 h, within a water bath at 37 ˚C.
Adhesive samples of 60 µL were applied at the end of one strip and covered with another
strip to create a 1 cm2 contact area between the collagen faces. The final specimens were
kept at 37 ˚C in a water bath for 1 hr to cure and then loaded in a MTS Synergie 100
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(Eden Prairie, MN) machine. The uniaxial crosshead speed was kept constant at 10
mm/min.
In order to explore indicators for the mechanical compliance of these samples from
the lap shear testing, two other variables were defined, extension at peak load (EPL) and
area under the load-extension curve (AUC). The first measure is simply the relative
separation of the two fixtures in mm at the maximum registered load value; and the area
under the curve, expressed in units of energy (mJ = N x mm), was calculated from the
origin up to 3 mm in the horizontal axis. This arbitrary extension limit was set due to
availability of data collected in the lap shear tests.

3. 5 Degradation profiles characterization
Degradation profiles were determined as mass loss percentage of adhesive samples
incubated in 1x PBS at 37 ˚C for 2, 5, 10, 15, 17, 19 and 21 days. The 50-µL adhesive
samples were casted in circular molds to get uniform disc-shape specimens (Figure 3.4),
and left within a water bath at 37 ˚C to crosslink overnight. Samples were then recovered
from the molds and subjected to an initial incubation in 1x PBS at 37 ˚C overnight to
remove any unreacted monomers from the sample. Then, they were freeze-dried
overnight and weighted, to register the initial dry weight (Wdo). After that, all samples
were incubated again under low speed shaking, in 4 mL 1x PBS at 37˚C and collected at
specific time points. Collected samples were freeze-dried and weighted to get the dry
weight at time t (Wdt). Finally, the mass loss percentage was calculated based on the
following equation:

𝑊-. − 𝑊-0
𝑊-.
×100

%𝑚𝑎𝑠𝑠 𝑙𝑜𝑠𝑠(𝑡) =
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A

B

Figure 3.4 A) Molds used to cast the disc-shape samples, consisting of a thin EVA rubber sheet
glued onto microscope glass slides (8-mm diameter circles were cut from the EVA rubber sheet).
B) Crosslinked samples retrieved from the mold, before incubation.

3. 6 Statistical analyses
All continuous variables were compared with one-way analysis of variance
(ANOVA) with Tukey’s Honestly Significantly Difference (HSD) as the post-hoc testing
to identify individual effects. Differences in mean values were considered significant if
associated with a p-value of <0.05.
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CHAPTER FOUR
RESULTS

4.1 Polymers functionalization
4.1.1 ACRYLATION
Both T1107 and T304 were acrylated (T1107-ACR and T304-ACR) with a target
conversion of 100%, and T1107 was also partially acrylated to be further modified with
NHS. Based on the analysis of 1H-NMR spectra (Figures 4.1 and 4.2): (CDCl3, 300
MHz): δ = 1.1 (m, PPO CH3), 3.4 (m, PPO CH), 3.54 (m, PPO CH2), 3.65 (m, PEO CH2),
4.32 (t, −CCH2OC(=O)−), 5.8 and 6.4 (d, 2H, acrylic −CH2), and 6.15 (q, 1H, acrylic
−CH) ppm, conversion efficiencies were calculated as the ratio of the integrals of the
polymer backbone (δ = 3.4-3.7 ppm) and one acrylate proton (δ = 6.4 ppm) (Table 4.1).
The peak seen in the NMR spectrum of T1107-ACR at approximately 2.3-2.4 ppm
(Figure 4.1) does not belong to Tetronic, and is thought to be generated by the presence
of water traces in the sample.104 Acrylation reactions that resulted in low conversion
efficiencies of T304-ACR showed 1H-NMR spectra with unusual peaks at approximately
1.2 and 3-3.1 ppm, and also exhibited changes in physical properties such as color and
density compared to the highly acrylated T304-ACR (Figure 4.3). 1H-NMR simulations
were run to assess whether crosslinked acrylates matched the unusual peaks on the actual
NMRs (Figure 4.4).
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4.1.2 NHS ADDITION
NHS groups were attached to the unmodified arms of partially acrylated T1107 to
form T1107-ACR-NHS. NHS conversion efficiency was calculated based on 1H-NMR
(CDCl3, 300 MHz): δ = 1.1 (m, PPO CH3), 2.85 (m, NHS CH2), 3.4 (m, PPO CH), 3.54
(m, PPO CH2), 3.65 (m, PEO CH2), 4.32 (t, −CCH2OC(=O)−), 5.8 and 6.4 (d, 2H, acrylic
−CH2), and 6.15 (q, 1H, acrylic −CH) ppm (Figure 4.5). A first approach accounts for the
ratio of the integral of the PPO CH3 (δ = 1.1 ppm) to the integral of the NHS CH2 (δ =
2.85 ppm). A second approach is based on the ratio of the integral of the proton of the last
EO unit (δ = 4.32 ppm) to the integral of the NHS CH2 (δ = 2.85 ppm).

Table 4.1 Conversion efficiencies.
Base polymer
T1107
T1107
T304
T1107-ACR

Functionalization
Acrylation
Acrylation
Acrylation
NHS addition

Target conversion
100%
50%
100%
50%

Actual conversions
86-94%
61%
78-82%
30-39%

Figure 4.1 1H-NMR spectrum of T1107-ACR.
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Figure 4.2 1H-NMR spectrum of T304-ACR.

A

B

C

Figure 4.3 Characteristics of product from unsuccessful T304 acrylation. A) 1H-NMR spectrum
of low conversion T304-ACR. B) same T304 used to run NMR in A) after centrifugation at 0 ˚C,
4000 rpm, for 10 min, showing two separated phases of different color and density. C) solid
material recovered by paper-filtration after precipitation in ether at room temperature.
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Figure 4.4 1H-NMR predictions of T304-ACR (upper image) and T304-ACR with crosslinked
arms and linked to others T304-ACR (lower image). Note: to simplify simulations PPO blocks
contain one PO unit in these predictions and PEO, two EO units.
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Figure 4.5 1H-NMR spectrum of T1107-ACR-NHS.

4.2 Thermal gelation characterization
4.2.1 Calibration for testing conditions
A first set of experiments was conducted with 30 wt% polymer solutions of T1107ACR, T1107-ACR-NHS and T304-ACR at weight percentage ratios (XX:YY:ZZ =
T1107-ACR:T1107-ACR-NHS:T304-ACR). Initially, the gap between two plates was set
at 200 µm, which turns out to be too high for those formulation with higher contents of
T304-ACR and lowered to 150 µm for 50:50 and 25:75 formulations (Figure 4.4). The
other formulations, 100:0 and 75:25, had been tested at 200 µm and experiments were not
repeated at 150 µm. Original sample volumes of 350 µL were modified to 270 µL to
account for the new reduced gap size. The gelation temperatures increased as the amount
of T304-ACR increased. Formulation 0:25:75 was significantly higher than any other
formulation; 0:50:50 and 0:75:25 were only significantly higher than 100:0:0 (Figure
4.5). Other differences were not statistically significant.
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Figure 4.4 Schematic of rheometer plates and sample distribution. A) incomplete contact
between sample and geometry with a 200-µm gap. B) full contact with a 150-µm gap.
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Figure 4.5 Preliminary results on gelation temperatures. *Gap=200µm; †Gap=150 µm. n = 3 for
100:0:0, 0:100:0, and 0:75:25, n = 7 for 0:50:50, and n = 5 for 0:25:75.

4.2.2 COMPREHENSIVE RHEOLOGY STUDY
Two different polymer concentrations were tested at 30 wt% and 35 wt%. The ratio
of T1107-ACR-NHS was held constant at 25 wt% of total polymer weight, and T1107ACR and T304-ACR were modified in 25-wt% steps.

54

Formulations made at a polymer concentration of 35 wt% exhibited sol-gel transition
temperatures consistently lower than their 30 wt% counterparts, though this difference
was not significant for 75:25:0 samples (Figure 4.6 and Table B.1). At the same polymer
concentration, the gelation temperature increased as the T304-ACR content increased.

30
30 wt%

GELATION TEMPERATURE [˚C]

25

26.5
23.2

35 wt%
19.8

20

16.8

15.8

14.3

15

10

5

0
75:25:00

50:25:25

25:25:50

T1107-ACR : T1107-ACR-NHS : T304-ACR BLENDS

Figure 4.6 Gelation temperature. Errors bars ± 1 SD.

Sol-gel transitions are accompanied by changes in viscosity, storage modulus (G’),
loss modulus (G”), and delta angles for each individual sample which were highly
dependent on sample formulation (Figure 4.9). G’ was significantly different between
different formulations at the same polymer concentrations, but similar between same
formulations at different concentrations except for 50:25:25 (Figure 4.7, Table B.2). G”
was significantly different in pairwise comparisons with the exception of the following,
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75:25:0 – 35 wt% vs. 50:25:25 – 35 wt%, 75:25:0 – 30 wt% vs. 50:25:25 – 30 wt%, and
25:25:50 – 35 wt% vs. 25:25:50 – 30 wt% (Figure 4.7, Table B.3). At physiological
temperatures G’ was larger than G”, however, the ratio G”/G’ increased with higher
contents of T304-ACR, noted by delta angles changes (Figure 4.8). Viscosity at
physiological temperatures ranged from 134 to 3583 Pa.s, and before gelation from 0.015
to 0.229 Pa.s, but there were no significant differences between any group in each
variable.
Formulation 0:25:75 at 30 wt% was not included in statistical analysis due to
inconsistent results that yielded mean values that were not representative of the whole
series. All recorded rheology measurements for this sample were included in Table 4.3.

Table 4.3 Rheology results from formulation 0:25:75 – 30wt%.
Sample # Gelation
Average G’ at
Average G” at
Average Delta at Average Viscosity at
(batch #) temp [˚C] physiological temp physiological temp physiological temp physiological temp
[kPa]
[kPa]
[degrees]
[Pa.s]
1 (1) No gelation
0.00
0.00
92.6
0.06
2 (1)
24
0.58
0.23
21.6
1638.12
3 (1)
24
0.56
0.22
21.6
323.32
4 (1)
27
0.36
0.14
21.8
729.78
5 (2) No gelation
0.00
0.00
92.2
0.07
6 (2)
28
0.22
0.09
23.1
357.28
7 (2)
29
0.09
0.04
25.9
931.22

56

50

45
40

30 wt%

41.8
38.4

35 wt%

35
30
24.4

25
20
14.7

15
10
5

0.7

1.5

Loss modulus (G") at physiological temp
[kPa]

Storage modulus (G') at physiological temp
[kPa]

50

0

30 wt%

45
40

35 wt%

35
30
25
20
15
10
4.4

5

5.0

2.8

3.0

0.3

0
75:25:00

50:25:25

25:25:50

75:25:00

T1107-ACR : T1107-ACR-NHS : T304-ACR BLENDS

50:25:25

0.7

25:25:50

T1107-ACR : T1107-ACR-NHS : T304-ACR BLENDS

Figure 4.7 Storage (G’) and loss (G”) moduli at physiological temperature. Errors bars ± 1 SD.
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Figure 4.8 Delta angle at physiological temperature. Errors bars ± 1 SD.
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Figure 4.9 Example of viscosity, G’ and G”, and delta charts obtained from rheology analysis on
one individual sample. Results corresponds to a 25:25:50 – 35 wt% sample.
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Figure 4.10 Viscosity before gelation and at physiological temperature. Errors bars ± 1 SD.

4.3 Adhesive strength
4.3.1 PEAK ADHESIVE STRENGTH
The characterization of adhesive bond strength was done by normalizing the peak
load (force at failure) by the contact area in a lap shear test.4 Twelve combinations were
tested in preliminary studies to adjust preparation methods. Five out of these twelve
combinations exhibited either extremely rapid thermal gelation (due to high T1107
content) or chemical crosslinking (due to high acrylates content), that occurred in 1-5 s,
for both types of solidification. That time was not enough to allow for mixing and
application. For this reason, these combinations of polymer formulation and
concentration were not included in any of the testing plans.
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The adhesive bond strength ranged approximately from 28 to 83 kPa and decreased as
T304-ACR contented increased (Figure 4.11). Samples with higher polymer
concentration (35 wt%) showed similar to or lower bonding strengths when compared to
their less concentrated counterparts (30 wt%).

Table 4.4 Testing matrix. Green cells correspond to combinations that were actually tested, while
red cells represent combination that were not tested.
Hydrogel formulations
50:25:25
25:25:50

75:25:00
Polymer
concentration

30%

✓

✓

✓

35%

✓

✓

✓

Gels too
fast

Gels too
fast

Crosslinked
too fast

40%

0:25:75

✓
Crosslinked
too fast
Crosslinked
too fast

110

30 wt%

BONDING STRENGTH [kPa]

100
90

35 wt%

82.8

80
70

65.8

69.5

60
50
38.5

40

44.0
28.0

30

27.7

20
10
0
75:25:00

50:25:25

25:25:50

0:25:75

T1107-ACR : T1107-ACR-NHS : T304-ACR BLENDS

Figure 4.11 Peak adhesive bond strength. Errors bars ± 1 SD.
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4.3.2 MODE OF FAILURE
The samples that showed the highest adhesive strength failed mainly cohesively,
while, in decreasing order of adhesive strength, 50:25:25 – 30 wt% and 75:25:0 had a
higher adhesive fail count.
A)

B)

Figure 4.12 Mode of failure. A) adhesive (25:25:50 – 30 wt%). B) cohesive (50:25:25 – 35 wt%).

Table 4.4 Modes of failure.
Formulation
75.25.00 – 30wt%
50:25:25 – 30wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%

Adhesive Failure
n (%)
1 (20.0)
3 (60.0)
1 (20.0)
1 (20.0)
4 (80.0)
1 (6.7)
4 (30.8)

Cohesive Failure
n (%)
4 (80.0)
2 (40.0)
4 (80.0)
4 (80.0)
1 (20.0)
14 (93.3)
9 (69.2)

4.3.3 LOAD-EXTENSION ANALYSIS
EPL showed to be a disperse measurement with high variability. Formulations at 30
wt% exhibited a decreasing trend whit higher T304-ACR content, but 35 wt%
formulations did not show such a clear trend (Figure 4.12) The results included outliers
and extreme values in these series, but even when they were removed, a post-hoc analysis
showed only two other significant mean differences of 0.7 mm (between 0:25:75 – 30
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wt% and 50:25:25 – 35 wt%, and 0:25:75 – 30 wt% and 25:25:50 – 35 wt%, data not
shown).
The AUC ‘load vs. extension’ accounts for the strain energy or work subjected by the
adhesive at a certain extension (3 mm in this analysis). The sample groups with higher
adhesive strengths, namely 75:25:00 – 30 wt% and 50:25:25 – 30 wt%, also exhibited
significantly higher AUCs when compared to any other formulation / concentration
(Figure 4.13, Table 4.4). Although the differences between these two groups were not
significant, the shape of the load-extension curves was different (Figure 4.15). While
70:25:00 – 30 wt% presented a quick rise and a slower drop (left shoulder), 50:25:25 – 30
wt% showed uniform rise and drop rates, resembling a bell shape.

Figure 4.13 Extension at peak load showing outliers (diamonds) and extreme values (circles).
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Figure 4.14 Area under the curve ‘Load vs Strain’ in lap shear tests. Errors bars ± 1 SD.
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Figure 4.15 Load-extension curves of the two formulation with the highest AUCs.
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4.4 Degradation profiles
The time to complete degradation was similar between different polymer
concentrations (Figure 4.10). Regardless the polymer concentration, all formulations
experienced a decrease in degradation rate with higher T304-ACR content. Data points
approximating the complete degradation time tended to show more variability, since at
this stage there were important differences among individual samples. For example, one
sample of 0:25:75 – 30 wt% completely disappear at day 17, much faster than the other
ones, and drove this average data point to almost an 80% of mass loss. Day 19 and day 21
for the same formulation actually showed lower average mass losses. This is not a gain in
mass on days 19 and 21 compared to day 17, but the effect of the sample that was
unexpectedly fully degraded by day 17.
Although swelling ratios were not assessed, the hydration of the polymer networks
and subsequent swelling was evident, even in the 0:25:75 – 30 wt% samples from their
change in size (Figure 4.17).

64

TIME [DAYS}
0
100%

MASS LOSS [%]

2

4

6

8

10

12

14

16

18

20

10

12

14

16

18

20

Polymer concentration: 35wt%
75:25:00
50:25:25

80%

25:25:50
60%
40%
20%
0%

MAS LOSS [%]

100%

Polymer concentration: 30wt%

80%

75:25:00
50:25:25

60%

25:25:50
40%

00:25:75

20%
0%

0

2

4

6

8

22

24

TIME [DAYS]

Figure 4.16 Degradation profiles. Errors bars ± 1 SD.

Figure 4.17 0:25:75 – 30 wt% samples used for degradation study. Left image, dry sample before
incubation. Right image, same sample after 15 days of incubation.
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CHAPTER FIVE
DISCUSSION
Previous studies have shown the potential of Tetronics to create hydrogel platforms to
be used as tissue adhesives.46,59,89 In our research group, Sanders and coworkers
developed a Tetronic-based material that incorporated acrylates for covalent crosslinking
and NHS for tissue binding which exhibited excellent adhesive strength, but their sol-gel
transitions occurred well below room temperature.4 This thesis project aimed to build on
these successful results, maintaining the same end-group chemistry to retain the good
adhesive properties, while introducing a smaller molecular weight Tetronic, T304-ACR,
to control the gelation temperature of these systems. Based on another study carried out
in our lab,102 that showed that unmodified T1107 gelled at higher temperatures when
blended with unmodified T304, it was hypothesized that the incorporation of T304-ACR
could be a valid strategy to increase gelation temperature without significantly
compromising the mechanical properties of the original blend.

5.1 Polymers functionalization
In the present study, reactions for acrylation and NHS addition on T1107 were
conducted following established protocols, and the conversion efficiencies were
comparable with those already published.46,59,4 The acrylation reaction of T304 is similar
to that of T1107, but due to differences in molecular weight and solubility of these
polymers, development of a different approach was required when purifying the final
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product. A previous study in our lab preparing T304-ACR102 used a protocol developed
for the acrylation of T904,5 and resulted in 62-74% acrylation efficiency. In our first
attempt using this protocol, a 76% conversion was achieved. However, subsequent T304
acrylation reactions resulted in lower conversion (30 - 57 %), and 1H-NMR
characterization consistently revealed unusual peaks at 1.2 and 3.0-3.1 ppm (Figure 4.3).
Presence of impurities or solvent traces as the cause of these extra peaks was ruled out
since additional precipitation steps in ether/hexane solutions, and extended vacuumdrying periods (up to 129 hours) did not improve the results.
Our hypothesis for the low acrylation conversions was auto-crosslinking of T304ACR. It was observed that the product changed in color from dark orange to a pale
yellow, became much more viscous (closer to a paste instead of a thick liquid), and
solubility in ether decreased appreciably. These findings suggest presence of larger
polymer molecules that resulted from crosslinking in the sample mixture. Furthermore,
when a simulation of proton NMR spectrum for crosslinked T304-ACR units was
performed, we were able to reproduce the extra peaks found in the actual NMRs. Based
on these results, we took several measures to prevent T304-ACR from crosslinking itself.
For example, to keep acrylates away from their reactive form, the rotary evaporations
were performed at room temperature, instead of 25-30 ˚C. In addition, to avoid long
exposures to low pressure conditions, the vacuum-drying steps were kept at 4-8 hours,
and performed on ice bath to keep the temperature low. Finally, we incorporated a paperfiltration step to remove the remaining large crosslinked molecules. With these
modifications, the acrylation efficiency increased up to 82%. Although the removal of
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crosslinked T304-ACR improved the acrylation efficiency of the final product, the
product yield was seriously harmed, and never showed values above 25-30%. It is
speculated that both the acrylation efficiency, and product yield could be further
improved by running the reaction under an oxygen-rich environment to lower the
acrylates activity.104

5.3 Thermal gelation characterization
To determine the gelation temperature of Tetronic-based adhesives, the tandem
gelation process was decoupled by omitting the addition of the thiol-containing
crosslinker. Notwithstanding the lack of covalent crosslinking, fully functionalized
Tetronics (with acrylates and NHS) were used to run this study. Gelation temperature
significantly (p < 0.05) increased from 14.3 ˚C with a T304-ACR-free formulation, to
26.5 ˚C with the formulation containing 50 wt% of T304-ACR. The increase in the
gelation temperature by the incorporation of T304-ACR is explained by the following.
The two main factors that determine the gelation temperatures in PPO-PEO block
copolymers are their molecular weight and HLB (PPO/PEO ratio).100 Thermal gelation is
an entropically driven process, governed by the hydrophobic segments. During gelation,
the longer PPO segments in T1107 (19 PO units/block compared to 4.3 in T304), release
far more free water molecules, creating a larger net entropy difference between solution
and gel states. According to Gibbs free energy equation, this higher entropy difference
would explain why lower temperatures trigger the gelation process in T1107 solutions.
Therefore, when T304-ACR was incorporated in these Tetronic formulations, the reduced
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amounts of T1107 species decreased their contribution to the reverse thermal gelation,
and gelation temperatures were increased as a result.
With the same formulation but at different polymer concentrations, blends at 35 wt%
exhibited sol-gel transitions at lower temperatures to that of 30 wt% blends. This is in
agreement with findings that proved the relationship between higher polymer
concentrations and lower gelation temperatures, with Pluronics,100,105 and Tetronics.106
From a free energy perspective, having more polymer molecules in solution increase the
entropy change when hydrophobic interactions are established, and thus the temperature
required to initiate this event is lower.
In addition to the gelation temperature, G’ and G” of the polymers exhibited changes
that are in accordance with the sol-gel transition when different formulations were
examined. Specifically, the G”/G’ ratio of these materials at physiological temperatures
indicated a shift from a strong solid-like to a more viscous behavior when formulations
incorporated T304-ACR. In other words, T304-ACR contributed to decrease the hydrogel
stiffness. Viscosity at physiological temperatures showed a general tendency to drop
when increased amounts of T304-ACR were used, in accordance with a decrease of their
solid-like character. This drop was the result of the augmented contribution of the lower
molecular weight, liquid T304 within the polymer network, that still needed an increase
in temperature to develop its thermal gelation.
Viscosity of samples before gelation is another useful parameter for characterization
of the products for the intended application. A reduction in gel viscosity means that it
could be delivered by smaller application tips and catheters, and should allow for a better
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diffusion of the crosslinker during mixing. Although, comparisons among different
groups did not result in statistical significant differences for this variable, these
differences where easily noted when handling these materials. Formulations without
T304-ACR were far thicker than those with it. This was evident when pipetting out
samples of 75:25:0 took longer times than any other formulation. The lack of statistical
significance between these samples’ viscosity could be due to the way data was
processed (averaging all values from 4 ˚C up to the temperature before gelation), or due
to the imposed shear rate during testing. More studies would be needed to study this
variable in more detail.
We also suspected that the auto-crosslinking issue could have happened even during
storage of concentrated product, or as part of polymer solutions. This could explain why
samples of 0:25:75 – 30 wt% exhibited inconsistent results in the rheology
characterization. It was expected that this formulation gelled at temperatures well above
25:25:50, if gelled at all within the testing temperature range. Surprisingly, most of these
samples underwent a sol-gel transition in the range of 24-29 ˚C. The samples could have
experience an unwanted auto-crosslink before or during the tests (favored by the
incremental increase in temperature) exhibiting a dual solidification via chemical and
thermal crosslinking. Future studies on the reversibility of the gelation experienced by
formulations with high concentration of T304-ACR, or the polymer size after the tests,
could help with the interpretation of these findings.
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5.4 Adhesive strength
The addition of increased amounts of T304-ACR resulted in lower average adhesive
strengths for both polymer concentrations (Figure 4.11) and consistently in a cohesive
failure mode (being 50:25:25 – 30 wt% the only exception). This combination of
outcomes indicates a decrease in bulk strength with higher content of T304-ACR, which
is somewhat contradictory to our initial idea. Specifically, we expected that the increased
number of available acrylates in T304-ACR containing formulations would lead to an
increase in crosslinking density, and thus, they should exhibit higher bulk strengths. The
results of the present study may be explained either by an incomplete crosslinking, or by
the formation of networks defects, or both. First, as we suspected as a potential problem
during synthesis and purification of T304-ACR, large auto-crosslinked T304-ACRs
would offer less acrylate groups to be linked by DTT because either they were committed
in the auto-crosslink, or they were immobilized at relatively fixed position where DTT
cannot reach. Second, the actual gel could be formed as a non-ideal network, i.e. not
every acrylate is involved in a linkage with another acrylate belonging to a different
molecule. These defects could be caused by many reasons, including stoichiometric
imbalances of reactants, incomplete conversions, and intramolecular reactions to form
non-crosslinking cycles.107 For instance, the reaction among a DTT molecule and two
adjacent arms of the same T304-ACR molecule would create a cycle, or loop that is
considered a structural defect because it decrease the ideal crosslink density (Figure 5.1).
Combining these two ideas, the auto-crosslink would offset the ratio of available
acrylates to thiol groups (stoichiometric imbalance of reactants), and thus, could increase
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the likelihood of these types of defects. This concept may be supported by the evidence
that using higher thiol to acrylate ratios (e.g., 2:1) almost completely prevented the DTTmediated crosslinking of acrylates (data not shown).
The results of the present study provide evidence that increasing polymer
concentration from 30 to 35 wt% also lowered the bonding strength of each formulation,
contradicting the expected increase in bulk strength due to a higher acrylates
concentration. Using the same rationale discussed in above, the hypothesis of autocrosslinked T304-ACR and imperfect gel networks could also explain these findings.
Interestingly, only the formulations that did not include T304-ACR (75:25:0) exhibited a
change in failure mode from cohesive to adhesive when moving from 30 to 35 wt%. This
not necessarily meant an increase in bulk strength, but at least did not contradict the
expected outcomes.

Figure 5.1 Formation of ideal crosslinks and a primary cycle, a defect in a non-ideal network.
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The load-extension curves from lap shear testing were explored to look for indicators
of mechanical compliance. Extension to peak load (EPL) analysis did not show any
conclusive result as to whether there was a formulation that allowed higher extensions
before reaching the peak load values. With no clear difference in EPL, formulations with
significant higher peak loads (75:25:0 and 50:25:25) exhibited the highest AUCs. The
most interesting finding, however, was the actual shape of these curves. While 75:25:0
samples did not show significant differences with 50:25:25 – 30 wt% samples in terms of
peak loads, the latter withstood larger extensions at the same load requirements.
Presumably, the imperfections introduced in the network formation with the addition of
T304-ACR allowed for a decreased crosslink density, thus producing a decrease in gel
stiffness. To confirm this hypothesis, uniaxial tensile testing of crosslinked hydrogels will
be necessary to assess the mechanical behavior.

5.5 Degradation profiles
The incorporation of T304-ACR in the adhesive led to a decrease in the degradation
rates. While the formulation without T304 (75:25:0 at 30 and 35 wt%) required 10 days
to complete degradation, the one with the highest T304 content (0:25:75 – 30 wt%)
exhibited an average of 76% mass loss at 21 days. This is likely due to the higher
hydrophobic character of T304 and the increased crosslink density. The thioether-ester
bonds resulting from Michael-type additions between acrylates and thiols can be
hydrolytically disrupted.108 Indeed, an ester bond in the vicinity of a thioether it is more
susceptible of hydrolytic attack that an unmodified ester bond or any of the other ether
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bonds presents in PPO and PEO.107 Thus, these ester bonds controls the degradation rates
in these polymers, which are known to exhibit bulk hydrolysis behavior.59 The water
invading the hydrogel network produce the bulk hydrolysis,109 and the loss of mechanical
properties should be expected much sooner than the time for full degradation.
Consequently, the good adhesive strength shown by 75:25:0 at 30 and 35 wt% and
50:25:25 at 30 wt% could be actually lower after significant swelling. Future research
could be conducted to characterize the effect of swelling and degradation over time on
the adhesive and bulk strengths, modifying standard lap shear and tensile testing to
account for the incubation periods to recreate the swelling and degradation processes.
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CHAPTER SIX
CONCLUSIONS AND RECOMMENDATIONS
In the present study, gelation temperature of modified Tetronics solutions showed a
strong dependence on T304-ACR content. The positive relationship between higher
T304-ACR content and increased gelation temperatures could be used as a strategy to
control and fine tune the thermoresponsive characteristics of Tetronic-based tissue
adhesives. However, with relatively high concentrations of T304-ACR, the increased
acrylates made the reaction to occur so fast that the overall result was having again a
material solidifying too fast. In addition, T304-ACR helped to significantly extend the
time to complete degradation. However, the bonding strength in lap shear tests was
reduced with increased amounts of T304-ACR. In conclusion, an appropriate blend ratio
(50:25:25 – 30 wt% in the present study) would help achieve the ideal balance of
increased gelation temperature, delayed degradation and adhesive bonding strength. The
following is a list with recommendations for future research to improve the
characterization and usability of Tetronic-based tissue adhesives, and to address the
limitations of the present study;
•

To study the stability of T304-ACR and to quantify the degree of “autocrosslinking” experienced when stored concentrated and in solution.
Rationale: it has been hypothesized that the inconsistent rheology findings
with 0:25:75 at 30 wt% and the unexpected decrease of bulk strength in lap
shear tests could be due to an unwanted crosslinking of T304-ACR not
mediated by DTT. Samples of pure T304-ACR and samples of this polymer in
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solution could be subjected to accelerated ageing methods before running 1HNMR characterizations or other tests to assess the molecular weight
distribution of the samples.
•

To replace the removal of rotary-evaporation step in T304-ACR synthesis by
a drying step consisting of dry-air purging. Rationale: Rotary evaporation is
used to concentrate T304-ACR when diluted in DCM. Vacuum and heat need
to be applied, presumably promoting crosslinking of the acrylate groups. A
simpler, less time consuming method consisting of purging the solution with
dry-air, could be enough to remove the solvent, without subjecting the sample
to heat or vacuum. A similar strategy could be used instead the vacuumdrying steps to remove solvent traces before product characterization.

•

To explore the effects of adding unmodified T304-ACR, or partially acrylated
T304-ACR to a 50:25:25 at 30 wt% sample. Rationale: higher contents of
T304-ACR showed decreased adhesive bonding strengths, but unmodified
T304 may not alter this property, while providing an additional way to bring
gelation temperatures to higher values. Blends of modified T1107 have shown
a solubility limit around 45-50 wt% in PBS, but T304 can be dissolved at
higher concentrations (data not shown) so there should be enough room for
unmodified T304 to be added to 50:25:25 – 30 wt% samples.

•

To experiment with the use of custom-designed Tetronic-like polymers
instead of using out of the shelf materials. Rationale: with the specific
molecular weight and HLB, a customized star-shaped PPO-PEO block
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copolymer could yield better overall results than the polymer blends of
commercially available polymers, and avoid issues related with different
polymer properties in the same blend. The ideal polymer should be of a size in
between T304 and T1107 to produce a reasonable crosslink density (to control
degradability and bulk strength) and PPO/PEO ratio could be used to further
control gelation temperatures if needed.
•

To assessed the impact of changing the crosslinker for the Michael-type
addition reaction. Rationale: the chain length of the thiol-containing
crosslinker has been associated with changes in the hydrolytic susceptibility of
the resulting thioether-ester bond.107 This may be an alternative to
deaccelerate degradation, while using the same base Tetronics.

•

To evaluate bonding strengths in more realistic models. Rationale: lap shear is
a good technique to compare adhesive strength among different samples, but it
is not a true recreation of natural loading conditions. A scale-up of the burst
pressure test with a punctured rad bladder previously used in our lab4 could be
considered, or new models such as vascular or intestine anastomoses glued
with the tissue adhesive and subjected to hydrostatic pressure.

•

To characterized the impact of T304-ACR on mechanical compliance with
soft tissues. Rationale: the shorter chains of T304 and presumably increased
crosslink density obtained with it should give stiffer hydrogel networks. A
simple tensile test could be performed to typified the differences in elastic
moduli and strain at failure with these formulations. A simulated cyclic

77

loading with an organ model (suggested in the previous point) could also
bring light to this matter as to which formulation is more compliant with
expandable organs.
•

To characterize the kinetics of the chemical crosslink and the time needed to
get full adhesive strength, and their dependence on pH. Rationale: the
chemical crosslinks are the responsible for the ultimate mechanical stability
and bulk strength of this type of crosslinked hydrogels. The time it takes the
hydrogel to be fully crosslinked will dictate the minimum time a surgeon
should wait before loading a treated wound. Michael-type addition reactions
with Tetronics are pH-sensitive.49 This attribute could be explored to control
the reactions rates, to allow for the incorporation of more T304-ACR without
experiencing immediate crosslinking.

•

To design a study to simultaneously evaluate swelling/degradation and
adhesive and/or bulk strength. Rationale: it is known that hydrogels networks
that experience bulk hydrolytic degradation also exhibit a significant
deterioration of mechanical properties along with the loss of internal integrity.
In the present study the initial adhesive strength has been characterized with
lap shear tests, but the decrease in bonding strength with the onset of
significant swelling/degradation has not been explored.
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Appendix A
Degradation: Pilot Study

A pilot study was first carried out to define the testing time length. Disc-shape
samples were crosslinked between glass coverslips, separated with 1-mm-Teflon spacers.
After 1-hr of curing period in a water bath at 37 ˚C, samples were incubated in 4 mL 1x
PBS in the same water bath, without shaking. Two samples for each formulation were
periodically checked by visual inspection until they were completely degraded. Table 4.6
lists the results obtained in this pilot study.
Table A.1 Degradation pilot study.
Formulation
100:00:00
75:25:00
50:50:00

Concentration
[wt%]
30
30
30

00:100:00

30

50:25:25

35

Time to complete
degradation [days]
12
12
11
Sample #1: 8
Sample #2: 6
18

Based on these results, the time length for the comprehensive study was set in 21
days, with data collection time points every 5 days until day 15, and every two days after
that. Glass coverslips and Teflon spacers were replaced for circular molds because
samples did not show a uniform thickness, and they were very susceptible to damage
during removal from the coverslip.
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Appendix B
Results from post-hoc statistical analyses

The following tables contain the mean differences between compared groups for
continuous variables and the associated p-value obtained in Tukey HSD tests. Bold
numbers mean significant difference. Findings from 0:25:75 – 30 wt% were not included
in statistical analysis due to high variability that yielded average values that were not
representative of the series. A table with these findings was included in Chapter 4.
Variables with non-significant mean differences in the one-way ANOVA were not
included in for the post-hoc analysis.

Table B.1 Pairwise post-hoc comparison (Tukey) on gelation temperature data.
Formulation 1

75:25:00 – 30wt%

50:25:25 – 30wt%

25:25:50 – 30wt%

00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%

Formulation 2
50:25:25 – 30wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 35wt%
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Mean Difference [˚C]
-4.00
-10.75
No comparison
1.41
-1.00
-7.45
-6.75
No comparison
5.42
3.00
-3.45
No comparison
12.17
9.75
3.30

Sig.
0.005
< 0.001
0.715
0.882
< 0.001
< 0.001
< 0.001
0.044
0.011
< 0.001
< 0.001
0.015

No comparison
-2.42
-8.87
-6.45

0.200
< 0.001
< 0.001

Table B.2 Pairwise post-hoc comparison (Tukey) on storage modulus at physiological
temperatures.
Formulation 1

75:25:00 – 30wt%

50:25:25 – 30wt%

25:25:50 – 30wt%

00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%

Formulation 2
50:25:25 – 30wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 35wt%

Mean Difference [kPa]
23.7
37.7
No comparison
-3.4
14.0
36.9
14.0
No comparison
-27.1
-9.7
13.2
No comparison
-41.2
-23.7
-0.8

Sig.
< 0.001
< 0.001
0.645
< 0.001
< 0.001
< 0.001
< 0.001
0.002
< 0.001
< 0.001
< 0.001
0.998

No comparison
17.5
40.3
22.8

< 0.001
< 0.001
< 0.001

Table B.3 Pairwise post-hoc comparison (Tukey) on loss modulus at physiological temperatures.
Formulation 1

75:25:00 – 30wt%

50:25:25 – 30wt%

25:25:50 – 30wt%

00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%

Formulation 2
50:25:25 – 30wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 35wt%
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Mean Difference [kPa]
-0.6
4.1
No comparison
1.6
1.4
3.7
4.6
No comparison
2.2
2.0
4.2
No comparison
-2.4
-2.6
-0.3

Sig.
0.589
< 0.001
0.004
0.006
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
0.899

No comparison
-0.2
2.1
2.3

0.996
< 0.001
< 0.001

Table B.4 Pairwise post-hoc comparison (Tukey) on delta angles at physiological temperatures.
Formulation 1

75:25:00 – 30wt%

50:25:25 – 30wt%

25:25:50 – 30wt%

00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%

Formulation 2
50:25:25 – 30wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 35wt%

Mean Difference [˚C]

Sig.

No comparison

No comparison

No comparison

No comparison

Table B.5 Pairwise post-hoc comparison (Tukey) on adhesive strength data.
Formulation 1

75:25:00 – 30wt%

50:25:25 – 30wt%

25:25:50 – 30wt%

00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%

Formulation 2
50:25:25 – 30wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 35wt%
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Mean Difference
13.32
38.81
55.15
16.99
44.36
54.84
25.50
41.83
3.67
31.04
41.52
16.34
-21.82
5.55
16.02
-38.16
-10.80
-0.31
27.37
37.84
10.48

Sig.
0.707
0.001
< 0.001
0.434
< 0.001
< 0.001
0.063
< 0.001
0.999
0.001
< 0.001
0.482
0.163
0.984
0.287
0.001
0.714
1.000
0.005
< 0.001
0.399

Table B.6 Pairwise post-hoc comparison (Tukey) for EPL.
Formulation 1

75:25:00 – 30wt%

50:25:25 – 30wt%

25:25:50 – 30wt%

00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%

Formulation 2
50:25:25 – 30wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 35wt%

Mean Difference [mm]
0.27
0.92
1.18
1.12
0.44
0.51
0.65
0.91
0.85
0.17
0.25
0.25
0.19
-0.49
-0.41
-0.06
-0.74
-0.66
-0.68
-0.60
0.08

Sig.
0.976
0.067
0.008
0.013
0.606
0.434
0.372
0.076
0.117
0.994
0.962
0.982
0.996
0.488
0.703
1.000
0.077
0.167
0.130
0.259
1.000

Table B.7 Pairwise post-hoc comparison (Tukey) for AUC.
Formulation 1

75:25:00 – 30wt%

50:25:25 – 30wt%

25:25:50 – 30wt%

00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%

Formulation 2
50:25:25 – 30wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 30wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
00:25:75 – 30wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
75:25:00 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
50:25:25 – 35wt%
25:25:50 – 35wt%
25:25:50 – 35wt%
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Mean Difference
2.59
11.97
13.38
8.11
11.11
12.38
9.38
10.79
5.52
8.52
9.78
1.40
-3.87
-0.863
0.399
-5.27
-2.28
-1.01
3.00
4.26
1.26

Sig.
0.274
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
0.875
0.021
0.965
1.000
0.001
0.202
0.935
0.033
0.001
0.517
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